ERJ Express. Published on September 15, 2011 as doi: 10.1183/09031936.00047010

The adipose tissue in obesity and obstructive sleep apnea

Maria R Bonsignore[1,2], Walter T McNicholas[3], Josep M Montserrat[4] and Jürgen Eckel[5]

[1]Biomedical Department of Internal and Specialistic Medicine (DIBIMIS), Section of Pneumology, University of Palermo, Italy; [2]Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy; [3]Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland; [4] Sleep Laboratory, Hospital Clinic-IDIBAPS CIBERES, Barcelona, Spain; [5]German Diabetes Center, Düsseldorf, Germany

Running head: OSAS, obesity and metabolism

Body of text: 9746 words

Address correspondence to:

Maria R Bonsignore, MD

Biomedical Department of Internal and Specialistic Medicine (DIBIMIS), University of Palermo

c/o V Cervello Hospital

Via Trabucco 180

90146 Palermo, Italy

e-mail: marisa@ibim.cnr.it

Acknowledgements

The content of this review is based on the data presented during the Joint ERS-COST Actions B26 and BM0602 Research Seminar held in Palermo, Italy during October 2009 by:

Maria R Bonsignore, Palermo, Italy (Chair of the Seminar)

Jürgen Eckel, Düsseldorf, Germany (Co-Chair of the Seminar, Chair of COST Action BM0602)

Walter T. McNicholas, Dublin, Ireland (Chair of COST Action B26)

Leila Kheirandish-Gozal, Chicago, IL, USA

Francesco Giorgino, Bari, Italy

Thorarinn Gislason, Reykjavik, Iceland

Ronald R Grunstein, Sydney, Australia

Craig L Phillips, Sydney, Australia

Vsevolod Y Polotsky, Baltimore, MD, USA

Renata Riha, Edinburgh, UK

Shlomo Sasson, Jerusalem, Israel

Paul Trayhurn, Liverpool, UK

Stijn Verhulst, Antwerp, Belgium

ABSTRACT (197 words)

An ERS Research Seminar on "Metabolic alterations in obstructive sleep apnea (OSA)" was jointly organised in October 2009 together with two EU COST Actions ("Cardiovascular Risk in the Obstructive Sleep Apnea Syndrome" - Action B26, and "Adipose Tissue and the Metabolic Syndrome" - Action BM0602) in order to discuss the interactions between obesity and OSA. Such interactions can be particularly significant in the pathogenesis of metabolic abnormalities and increased cardiovascular risk in OSA patients. Studying the respective role of OSA and obesity, however, is difficult in patients, making it necessary to refer to animal models or in vitro systems. Since most OSA patients are obese, their management requires a multidisciplinary approach. This review summarizes some aspects of the pathophysiology and treatment of obesity, and the possible effects of sleep loss on metabolism. OSA-associated metabolic dysfunction (insulin resistance, liver dysfunction, atherogenic dyslipidemia) is discussed from the perspectives of both obesity and OSA in adults and children. Finally, the effects of treatment for obesity or OSA, or both, on cardio-metabolic variables are summarized. Further interdisciplinary research is needed in order to develop new comprehensive treatment approaches aimed at reducing sleep disordered breathing, obesity and cardiovascular risk.

Keywords: obesity, adipocyte, hypoxia, dyslipidemia, liver dysfunction

1. **INTRODUCTION**

The obesity epidemic worldwide has fostered ~~intense~~ investigation on adipose tissue, to prevent the morbidity linked to obesity and develop effective treatment. Obesity is a risk factor for diabetes and cardiovascular events [1,2], and increases mortality especially in middle-aged adults [3]. Obesity rates are also rising in children [4 5]. Since obese children tend to become obese adults [6], the cardiometabolic disease associated with obesity could begin in childhood [7]. ~~making pediatric obesity a major challenge for Public Health worldwide~~.

Adipose tissue is ~~currently considered as~~ a central player in metabolic regulation through production and release of multiple adipokines [8]. Moreover, adipocytes and inflammatory cells such as macrophages show a high degree of interaction in obesity [9,10]. The resulting picture is complex and yet incomplete, and recent research has explored new directions, such as the pathophysiology of different fat depots in the body [11], the role of hypoxia [12], and the interactions between adipose tissue and the central nervous system in response to nutrient excess [13]. Obesity has also been related to the chronic sleep loss typical of the current lifestyle in both adults and children [14,15].

Obesity is a common finding and a major pathogenetic factor in obstructive sleep apnea (OSA) in adults [16,17] and children [18,19 20]. OSA is characterised by recurring episodes of upper airway obstruction during sleep [21], intermittent hypoxia [22], sleep fragmentation [23], excessive daytime sleepiness [21], and increased cardiovascular risk [24]. Upper airway collapse during sleep can be prevented by application of nasal continuous positive airway pressure (CPAP), which is the treatment of choice for moderate-severe OSA in adults. In children, OSA is traditionally considered as a “local” disease due to high prevalence of adenotonsillar hypertrophy, and adenotosillectomy is usually

performed; however, ~~only~~ partial resolution of OSA is often observed, which likely reflects the additional impact of obesity [25,26].

Changes in body weight are known to affect OSA severity [27-29]. Most adult patients with OSA have *central* obesity and increased visceral fat [30], the latter being associated with neck adiposity, increased upper airway fat [31] and metabolic abnormalities [32] even in normal-weight subjects. Gender-related differences in the amount of visceral fat [33] could contribute to the higher prevalence of OSA in men. In children, besides the classic OSA phenotype associated with adenotonsillar hypertrophy [34] and growth failure [35], it is possible to identify an obese OSA phenotype, similar to adult OSA [34].

It is conceivable that OSA and obesity may interact and potentiate their detrimental consequences. OSA-associated metabolic abnormalities have been reproduced in animal models exposed to a pattern of intermittent hypoxia similar to that found in humans with sleep-disordered breathing [36,37]; on the other hand, hypoxia of adipocytes could play an important role in the metabolic disturbances associated with obesity [8,38]. In addition, OSA and obesity share common mechanisms such as inflammatory activation [39], oxidative stress [39] and increased sympathetic activity [40].

To discuss the complex relationship between OSA and obesity, the second Research Seminar on the "Metabolic effects of OSA" was organised in October 2009 by the ERS and two EU-funded Actions of the COST program (COoperation in Scientific and Technological Research), namely the COST Actions B26 on "OSA and Cardiovascular Risk" and BM0602 on "Adipose Tissue: a Key Target for Prevention of the Metabolic Syndrome". The first Seminar had taken place in 2007, and its focus had been primarily on the pathogenesis of insulin resistance (IR) in OSA [36].

The purpose of this review is to provide an overview on the pathophysiology of obesity, including an essential description of the main aspects of adipose tissue biology, the pathogenesis and the implications of IR in tissues such as skeletal muscle and liver, the possible role of sleep loss in obesity, and current treatment for obesity. With this background, the role played by OSA in the pathogenesis of metabolic abnormalities in adults and children will be briefly reviewed, together with the effects of OSA treatment. The outline of the paper is reported in Table 1. As for genetic interactions between OSA and obesity, which were also discussed during the Seminar, the interested reader is referred to recently published reviews [41-43].

2. ADIPOSE TISSUE PATHOPHYSIOLOGY, INSULIN RESISTANCE AND METABOLIC SYNDROME

The aim of this Section ~~of the review~~ is to discuss some features of obesity that are important in the context of OSA, namely, the types and distribution of adipose tissue in obesity, and the mechanisms of adipocyte dysfunction.

2.1 Types and distribution of adipose tissue in obesity

Adipose tissue exerts important endocrine functions involving multiple cross-talk with other organs and tissues [44]. Adipocytes produce hormones, cytokines and many other proteins and peptides, collectively called «adipokines», leading to fine tuning of fuel utilization, energy homeostasis, and cardiovascular function [8,45-47]. In addition, pre-adipocytes, lymphocytes, macrophages and endothelial cells contribute to

the secretory output of adipose tissue and play a key role for the endocrine activity of the different fat depots.

Obesity is characterized by the expansion of white adipose tissue, as a result of increased size (hypertrophy) and additionally by an increased number of adipocytes (hyperplasia) [48]. The number and size of adipocytes vary according to localization of fat [48], diet [49], genetic factors [50], sympathetic innervation [51] and gender [52]. Visceral adiposity is generally associated with hypertrophy of adipocytes [53]. A modest amount of brown adipose tissue (BAT) is also present in humans, its main function being heat production rather than energy storage. The peculiar anatomical and functional characteristics of BAT have been recently summarized [54-56].

The localization of excess white adipose tissue in the body carries relevant metabolic consequences. Increased visceral fat mass is associated with more severe health effects compared to peripheral obesity, characterized by predominant accumulation of subcutaneous fat [57]. The expansion of visceral fat increases the risk of developing insulin resistance (IR), type 2 diabetes, atherosclerosis, OSA, steatohepatitis, and cardio- and cerebrovascular disease [3,58,59]. Many clinical and biochemical factors associated with increased cardiovascular risk (i.e., dyslipidemia, arterial hypertension, hyperglycemia, hyperuricemia, and microalbuminuria) are often present in visceral (or central) obesity. The term “adiposopathy” has been proposed to indicate the strong link between visceral fat and obesity-associated metabolic abnormalities [60].

Recent data highlight the role of fat localization in modulating adipocyte function. Besides the classic distinction between visceral and subcutaneous fat, the latter can be subdivided into superficial and deep, with the deep fraction sharing many

features with visceral fat [61]. Ectopic fat depots can be found in the epicardial, periadvential and perirenal regions, in pancreas, skeletal muscle and bone marrow [47]. The physiology of adipose tissue in these localizations, and the cellular source of adipokines and inflammatory mediators, are incompletely understood but could contribute to the pathogenesis of obesity-associated abnormalities [47]. Specifically, epicardial fat is a true visceral fat depot and a tight association of epicardial fat mass with risk of cardiovascular disease has been recently reported [62].

Clinically, increased abdominal circumference is the best marker of visceral obesity and predicts overall mortality [3]. To improve the clinical recognition of central obesity, the "Metabolic Syndrome" (MetS) has been defined as the association of some risk factors (i.e., increased waist circumference, high blood pressure, and dyslipidemia) [59]. The widely used NHANES-ATP III definition is based on simple criteria [63], but its clinical or epidemiological usefulness is not entirely clear [64].

Identification of specific metabolic phenotypes may help to focus on high-risk patients. For example, about 20% of the obese population are metabolically healthy (MHO) [65]. The MHO phenotype is associated with early onset of obesity, predominance of subcutaneous over visceral fat, and a more favorable cardiovascular profile compared to patients with central obesity [66]. Adipose tissue in the gluteofemoral region may play an important protective role against metabolic abnormalities and the associated cardiovascular risk, by acting as a "metabolic sink" for excess fat storage (reviewed in [67,68]). The MHO phenotype might be more common in obese premenopausal women, who appear relatively protected from cardiometabolic risk [33] but show increased mortality associated with the MetS in the post-menopausal period [69]. Conversely, "normal-weight metabolically obese" (NWMO) subjects show an apparently lean

phenotype, but their amount of visceral fat is larger than normal and associated with insulin resistance [32,65]. There are some uncertainties about definitions [70], and longitudinal studies on cardiometabolic risk in obesity subtypes are still lacking.

The functional attitudes of visceral and subcutaneous adipocytes are programmed quite early during development and differentiation [71]. Adipocyte precursors are multipotent cells that reside in each fat depot and possess depot-specific genetic, biochemical and metabolic features [72]. Metabolic activity is higher in visceral than in subcutaneous fat [11], and adipocytes located in the abdominal region display distinct features compared to adipocytes from other depots [73,74] in both normal-weight and obese subjects. Visceral adipose tissue from nonobese humans responded faster and more intensely than subcutaneous adipose tissue to glucose or insulin exposure *in vitro*, with larger release of adiponectin, tumor necrosis factor-alpha (TNF-α) and leptin [11]. Visceral adipocytes from obese subjects released larger amounts of inflammatory cytokines, such as interleukin (IL)-1beta, IL-6, IL-8, and adipokines such as leptin, compared to visceral adipocytes from lean subjects [75]. Increased visceral fat and inflammation of adipose tissue were recently found in morbidly obese insulin-resistant subjects compared to weight-matched insulin-sensitive subjects, while the amount of subcutaneous fat was similar in the two groups [53]. Thus, a specific dysfunction of visceral adipocytes is considered as the pathophysiological basis for the negative consequences of abdominal obesity.

A thorough discussion of adipokines is beyond the scope of this paper (see [8,45-47,76] for further reading). Leptin and adiponectin will be briefly discussed since they exert complex and unique actions, and have been studied in patients with OSA. For both

adipokines higher circulating levels are found in females than in males [76], indicating that gender-related fat distribution may affect their expression and release [67].

Leptin is a polypeptide hormone produced by adipocytes in proportion to their triglyceride content, and is a major player in appetite regulation in the hypothalamus. Subcutaneous fat is the main site of production of leptin, and leptin release from samples of subcutaneous fat cultured *in vitro* correlates with the circulating leptin levels found *in vivo* in the same individuals [76]. Human obesity is usually associated with high plasma leptin and attenuated leptin signaling (leptin resistance) [77], while defects in the leptin or leptin receptor genes are rare in clinical practice but have been fundamental to understand the physiology of leptin in animal models [78]. Leptin might be involved in the pathogenesis of hypoventilation disorders [79] and its transcription is activated by exposure to continuous severe hypoxia *in vitro* [80]. In recent years, the role of leptin in immune function and inflammation has been increasingly studied [81], and some data indicate that leptin could contribute to the pathogenesis of atherosclerotic lesions by promoting inflammation [82]. All these data make leptin an interesting adipokine in the context of sleep-disordered breathing.

Adiponectin exerts an insulin-sensitizing action, and its levels are decreased in obesity [83-85]. Adiponectin has antiatherogenic and anti-inflammatory properties, and its circulating levels are lower than normal in patients with type II diabetes, metabolic syndrome, hypertension, and coronary artery disease [84]. Adiponectin is produced almost exclusively by mature adipocytes, and its expression is higher in subcutaneous than in visceral fat [86]. Importantly, adiponectin is found in the circulation in different oligomeric forms and it is now accepted that the so-called high-molecular-weight form is of key importance for the biological effects of this hormone [87] Inflammatory

mediators such as TNF-alpha [88], and both continuous [89] and intermittent [90] hypoxia were found to inhibit adiponectin production *in vitro*. Adiponectin levels increase after weight loss or treatment with several drugs, such as fibrates, angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, thiazolidinediones, statin, and some calcium channel blockers [91]. The protective role of adiponectin and its modulation by hypoxia suggest that it may be a useful marker of metabolic dysfunction in obesity and OSA.

2.2 Mechanisms of adipose tissue dysfunction in obesity

2.2.1. Inflammation

The recognition of inflammation as a major player in adipocyte dysfunction has been an important advance in obesity research. Inflammation was first reported to contribute to the pathogenesis of IR in 1993, when TNF-α expression was demonstrated in adipose tissue of obese rodents and insulin sensitivity was restored after treatment with anti-TNF-α antibodies [92]. A long list of inflammatory mediators are involved in obesity and IR [93], and obesity is considered as a state of chronic, low-grade inflammation [9]. As obesity develops, adipose tissue becomes infiltrated with macrophages [94]. Adipocyte-macrophage interactions contribute to development of IR, but other immune cells, like mast cells or lymphocytes, likely play a role [10,95].

The adipocyte can secrete inflammatory cytokines and attract monocytes by producing monocyte chemoattractant protein-1 (MCP-1) [94]. *In vitro*, adipocytes and macrophages show considerable similarities in their gene expression and functional aspects [10]. Both hypoxia [96] and decreased adiponectin [97] may play a role in macrophage

activation in obesity. In obese animals, macrophages are found in close relationship with dead adipocytes (crown-like structures) [98], suggesting that their recruitment is linked to phagocytosis of cellular debris. In addition, a shift from an anti- to a pro-inflammatory phenotype in adipose tissue macrophages has been demonstrated in both murine [99] and human [100] obesity. In obese subjects, adipose tissue macrophages show increased expression of TNF-alpha and inducible nitric oxide synthase (iNOS), according to the classic pro-inflammatory activation pattern (M1); conversely, in lean subjects adipose tissue macrophages predominantly show the alternative pattern of activation (M2) characterized by overexpression, among other molecules, of the antiinflammatory cytokine IL-10 [99].

Although inflammation contributes to the development of IR and MetS [9,93], the sequence of events leading to the inflammatory response in the adipose tissue is incompletely defined. An increased adipocyte size may be an important signal, through dysregulation of insulin signaling at the level of insulin receptor substrates (IRS). Phosphorylation of IRS-1, an early event in insulin signaling [101], is decreased in large adipocytes [102]. Adipocyte size in visceral fat correlated with IR in severely obese patients, and a smaller adipocyte size was found in MHO patients compared to patients with the classic visceral obesity phenotype [103]. Adipocyte size also correlated with proliferation of adipose tissue-derived progenitor cells [104].

Activation of the NFkB pathway further interferes with IRS-1 phosphorylation [10]. Nutrient excess causes endoplasmic reticulum (ER) stress, characterized by a complex disturbance in protein synthesis, in the adipocyte [105]. The pathways of inflammation and ER stress appear to intersect at some crucial points, involving the protein kinases JNK1 and IKKβ [95]. Finally, mitochondrial dysfunction was also

demonstrated in adipocytes exposed to hyperglycemia [106]. Therefore, inflammation impacts on several cellular pathways deeply disturbing adipocyte function.

2.2.2 Hypoxia

Expansion of adipose tissue causes oxygen deprivation in large adipocytes as their distance from the vasculature increases [12,107]. *In vitro* exposure of human and murine adipocytes to prolonged hypoxia decreased phosphorylation of IRS-1 and IRS-2 and caused IR [108 109]. Hypoxia in adipose tissue has been documented in obese humans [110-112] and mice [113,114]. In adipocytes in culture, continuous hypoxia stimulated the expression and secretion of several inflammation-related adipokines, including IL-6, leptin, angiopoietin-like protein-4 and vascular endothelial growth factor (VEGF) [113-115]. Continuous hypoxia inhibited the production of adiponectin [89], while intermittent hypoxia (12 cycles/h for 6 h/day) was recently found to inhibit adiponectin secretion while upregulating its expression in adipocytes [90].

Many effects of hypoxia are mediated by the hypoxia-inducible factor-1 (HIF-1), a transcription factor resulting from the dimerization of an alpha subunit, which is continuously degraded in the cytoplasm under normoxic conditions, and a beta subunit constitutively expressed by the cell [116]. When the oxygen level decreases, degradation of HIF-1alpha is inhibited and its cytoplasmic level increases, making it possible dimerization of HIF, its translocation to the nucleus, and the subsequent activation of transcription of several hypoxia-responsive genes [116].

Exposure to continuous hypoxia causes multiple adjustments in cell metabolism, including a switch to anaerobic glycolysis. In adipocytes, continuous hypoxia increased

the expression and protein level of the glucose transporter GLUT-1 [117], glucose uptake, and release of lactate [118 119], but decreased the expression of the insulin-dependent glucose transporter GLUT-4 [119]. Among the genes upregulated by hypoxia, expression of metallothionein-3 increased by 600-fold, suggesting a role possibly linked to its antioxidant properties [120]. Thus, *in vitro* data indicate that HIF-1α activation may directly cause IR in adipocytes [108]. However, a recent study in mice with defective expression of HIF-1α in adipose tissue found that these animals became more obese and insulin-resistant when exposed to a high-fat diet compared to wild-type mice [121]. Decreased energy expenditure associated with dysfunction of BAT appeared more important than IR in this *in vivo* model [121]. Therefore, further studies are needed to assess the role of hypoxia on brown and white adipose tissue in animal models and humans.

Recent measurements of tissue pO2 in lean rats during intermittent hypoxia or obstructive apnea cycles of comparable duration, showed that tissue pO2 oscillations were blunted in visceral adipose tissue [122], suggesting the possibility that changes in blood flow to adipose tissue might also occur in this model. More data are needed to better understand the effects of intermittent hypoxia on adipose tissue in order to assess whether specific alterations are responsible for the metabolic consequences of OSA.

2.2.3 *The lipoxygenase pathway and oxidative stress*

Besides hypoxia, other pathways may contribute to adipocyte dysfunction in obesity. Adipose tissue from high calorie-fed obese mice showed increased expression of lipoxygenases (LO) [123] whose products could promote recruitment and activation of

macrophages to and within the adipose tissue [124]. Knocked-out mice for 12-lipoxygenase gene (12-LOKO) on a high-calorie diet showed normal TNF-α, IL-6 and adiponectin release; in addition, MCP-1 concentration and the number of macrophages in adipose tissue were normal [123].

Oxidative stress could also play a role. 12-HETE directly controls the increased expression of MCP-1 in macrophages [125], and peroxidation products of HETEs may act as signaling molecules in adipocytes. For instance, 4-hydroxynonenal (4-HNE) exerts proinflammatory effects [126], but is normally neutralized by the enzyme glutathione-S-transferase (GST). Mice with disrupted GST gene gained more weight and accumulated more visceral fat in comparison with control mice, and showed high levels of 4-HNE in tissues [127].

As a summary of this Section, adipocyte dysfunction in obesity shows both metabolic and pro-inflammatory effects, likely reflecting disturbance of different cellular pathways. Even though knowledge of adipocyte biology has expanded greatly, the many facets of human obesity deserve further investigation. The emerging role of hypoxia and oxidative stress in the pathophysiology of obesity suggest possible interactions with OSA, in particular the activation of mechanisms common to both diseases.

3. INSULIN RESISTANCE AND METABOLIC SYNDROME IN OSA

Increasing severity of OSA in adults is associated with IR and the MetS [36,37,128], suggesting a link between OSA, metabolic abnormalities and cardiovascular morbidity

and mortality [24,129,130] [131-133]. However, the independent role of OSA is still unclear, due to the difficulty in separating the effects of obesity and sleep-disordered breathing in human studies.

Characterization of non-obese adult OSA patients is extremely poor as far as metabolic abnormalities are concerned. No MetS component was found in about 10% of OSA patients referred for a sleep study; these patients were younger and showed mild-moderate OSA compared to all other patients (Bonsignore, Barcelo et al, unpublished data). Absence of metabolic abnormalities might characterize an early stage in the natural history of OSA; alternatively, non-obese OSA patients could represent a distinct phenotype, as proposed for pediatric OSA [34].

On the other hand, increased visceral fat may be a critical factor also in non-obese OSA patients, who show increased fat deposition in the abdomen and neck compared to controls [134]. In a Japanese study, neck circumference normalized for height (NC/H) correlated with severity of OSA independent of visceral obesity, especially in non-obese subjects [135]. Finally, two studies in the general population recently reported that neck circumference is an independent predictor of cardiometabolic risk [136] and of both MetS and OSA [137], but sleep studies were not performed in either study.

Clearly, the role of neck fat deposition, which has been extensively studied in the past for its relationship to upper airway dimensions and function, deserves further attention with regard to metabolic problems in OSA. Non-obese OSA patients appear strikingly similar to the phenotype of metabolically obese normal weight (MONW) subjects [65]. However, no study to date has assessed cardiovascular risk or outcomes specifically in non-obese OSA patients.

While the association of OSA with increased visceral fat has been known for a long time, the impact of increased subcutaneous fat on OSA and metabolic variables is much less clear. A recent epidemiological study reported that visceral and subcutaneous fat are associated with IR with different strength [138], indicating that more work is needed in this field as clinical cardiovascular outcomes are concerned.

This Section briefly discusses some results of human and animal studies on the effects of intermittent hypoxia (IH) and OSA on IR and the MetS.

3.1 Clinical studies on metabolic abnormalities in OSA

Clinical and epidemiological studies have shown a progressive worsening of IR or MetS with OSA severity [139], [140-142] even in severe obesity [143], suggesting a causal role of OSA in metabolic derangements. In addition, there is evidence that IR develops during acute exposure to intermittent hypoxia in healthy humans [144]. Due to space constraints, the reader is referred to recent reviews on the complex relationship between OSA, glucose metabolism, insulin resistance and diabetes [37,128,145-150].

The main finding against a role of OSA in altered glucose metabolism is that IR did not improve after CPAP treatment in many studies (see section 6.2). At least part of the variability in results may be accounted for by the sensitivity of methods to detect IR, especially if one considers the peculiar condition of OSA patients who develop respiratory events only at night. For example, acute CPAP application in diabetic patients was found to decrease glucose level variability, as assessed by continuous glucose monitoring [151,152]. Similarly, glycosylated hemoglobin (HbA1c) could be a

sensitive marker of altered glucose metabolism in OSA in patients with [153] or without nondiabetes [154] , or with the MetS [155].

Both leptin and adiponectin have been studied in clinical OSA. Several studies have reported that OSA patients show increased leptin levels compared to BMI-matched controls [156-158]. Some studies found that AHI or severity of nocturnal hypoxemia were independent predictors of plasma leptin concentration [159,160], while others only confirmed the known association of leptin with obesity but no independent effect of OSA [161-164]. Most studies examined male OSA patients, and gender-related differences are still unknown.

Adiponectin, a metabolically protective adipokine, was found to be decreased in OSA patients compared to controls in proportion to the severity of nocturnal hypoxemia [165-167], suggesting a possible pathophysiological role of oxidative stress in decreased adiponectin levels in OSA. Other studies, however, reported a closer relationship of low adiponectin levels with obesity than with OSA [164,168]. A recent study found that, while daytime adiponectin levels correlated with several measures of obesity, the nocturnal fall in circulating adiponectin in OSA patients correlated only with the waist-to-hip ratio, suggesting that adipose tissue distribution may modulate nocturnal adiponectin levels [169].

Case-control studies conducted in MetS patients have provided other pieces of evidence on the effects of OSA on cardiometabolic variables. Compared to patients with MetS but no OSA, patients with MetS and OSA showed: a) more severe vascular dysfunction [170]; b) independent associations of OSA with triglyceride and glucose levels, C-reactive protein, uric acid and increased total/HDL cholesterol ratio [142]; and c) higher blood pressure and more severe autonomic dysfunction [171]. Similarly, in

hypertensive patients metabolic abnormalities were the strongest predictors of OSA [172]. It has been proposed that OSA should be considered as an additional component of the MetS [146,173]; recent findings in patients with MetS suggest that OSA may contribute to worsen metabolic abnormalities or could represent a marker of MetS severity[170 142 171].

Excessive daytime sleepiness (EDS) is a major symptom of OSA, and could be a marker of OSA severity. Two case-control studies reported that EDS predicts IR in OSA patients [174,175]; only sleepy patients showed improved insulin sensitivity after CPAP treatment for 3 months [174]. EDS in OSA patients was also found to be associated with type 2 diabetes [176]. Other studies, however, did not confirm the association of subjective EDS and a worse metabolic profile in MetS patients [142] or in morbidly obese patients [143] or in unselected consecutive OSA patients (Bonsignore, unpublished data). Therefore, the significance of EDS as a marker of metabolic abnormalities remains to be ascertained and is the focus of current clinical research.

3.2 The intermittent hypoxia mouse model

To better dissect the mechanisms by which OSA may affect metabolism, a mouse model of IH has been developed which reproduces some of the effects of human OSA [177]. Its main advantage is the possibility to study the response to IH in lean and fat animals in several tissues by mimicking the IH pattern occurring during the sleep in humans with OSA. The model has also some disadvantages, such as absence of intermittent hypercapnia [122] and occurrence of sleep disruption, characterized by a deficit in REM sleep and decreased delta power during non-REM sleep [178]. To

overcome these limitations, a model of OSA in rats was recently developed [179], but up to now has been used only in short-term studies.

In lean mice, acute IH caused IR [180], but IH for several days did not [181], possibly because prolonged exposure to IH was associated with failure to gain weight, which exerted positive effects on insulin sensitivity. In contrast, in mice with genetic or diet-induced obesity, chronic IH worsened IR [181].

There is no evidence that IH impairs pancreatic β-cell function, although β-cell proliferation and apoptosis occurred in mice exposed to IH [182,183]. IR during IH can be mediated via multiple pathways [177]. Among them, activity of the sympathetic nervous system did not appear to play a major role in the effects of acute IH in lean mice [180]. Acute IH increased corticosterone release, which could have contributed to IR [180]. The metabolic effects of IH were larger in obese compared to lean animals, suggesting that isolated IH may be insufficient to cause significant damage. The results of such experimental studies suggest the hypothesis that OSA could worsen metabolism in obese subjects while its effects might be limited in nonobese subjects, as recently found in a randomized controlled trial on the effects of CPAP on IR [184]. However, a previous study had reported different results, i.e., insulin sensitivity improved more in nonobese than in obese OSA subjects after CPAP treatment [185]. Therefore, the clinical impact of OSA and its treatment on IR requires further evaluation, especially in lean patients.

To summarize this Section, studies in both OSA patients and animal models indicate that OSA likely contributes to IR, even though its effect may be relatively minor compared to the effect of obesity. However, it should be underlined that human OSA is a multiple component disease, including intermittent hypoxia and sleep fragmentation. The respective contribution of respiratory and polysomnographic

parameters to metabolic variables in OSA patients is also a clinically important issue, but could not be addressed in this review due to space limitations.

4. ECTOPIC FAT AND DYSLIPIDEMIA

The metabolic abnormalities of adipocytes in obesity are further amplified by ectopic fat deposition [44]. As storage capacity of adipose tissue is overwhelmed, decreased insulin action in adipose tissue increases lipolysis and release of free fatty acids (FFA) into the circulation, and IR develops in peripheral tissues (the "lipotoxicity" picture) [186-190]. The main targets of FFA in this "overflow hypothesis" [44] are skeletal muscle and the liver (Figure 1).

Obesity increases the amount of perivascular adipose tissue. Previously considered to exert mainly a mechanical support function, perivascular fat has been recently shown to normally exert a vasorelaxant action [191]. Obesity and the associated IR appear to blunt the physiological effect of perivascular fat, causing vascular dysfunction in obese animals [192] and humans [193], with obvious implications for the pathogenesis of cardiovascular disease associated with obesity.

The possibility that ectopic fat deposition may affect pancreatic exocrine function has been recently explored. Pancreatic fat deposition was found in mice fed a high-fat diet and in pathology specimens from patients with type 2 diabetes, in the form of adipocyte infiltration and modified lipid content of pancreatic exocrine tissue [194]. In obese subjects, pancreatic fat deposition increased with increasing visceral fat in men [195] but, besides its association with IR, no clear effect of beta-cell function could be demonstrated [196]. Therefore, the pancreas might also be a target in visceral obesity, but

more studies are needed to verify the clinical importance of pancreatic fat accumulation on exocrine and endocrine function.

The available information on the effects of obesity, OSA and experimental IH on muscle and liver metabolism is summarized in the following subsections.

4.1 Skeletal muscle adipose tissue in obesity and OSA

Obese subjects show increased intra- and intercellular fat deposition in skeletal muscle [189,197]. By releasing endocrine and metabolic mediators (including TNF-α, IL-6, leptin, and adiponectin), adipose tissue cross-talks with skeletal muscle, a process that precedes and underlies the development of muscle IR [189]. IR in skeletal muscle is strongly linked to elevated adipose tissue mass [188,189].

IR in skeletal muscle was initially hypothesized to be secondary to the increased availability of FFA, with subsequent activation of fat oxidation and inhibition of glucose utilization. This hypothesis predicted intracellular accumulation of glucose-6-phosphate (G6P), due to inhibition of the early steps of glycolysis. However, exposure to FFA was shown to decrease, not increase, intracellular G6P concentration. Therefore, similar to what happens in adipose tissue, impaired insulin-dependent glucose transport plays a major role in skeletal muscle IR (reviewed in [198]). Macrophage infiltration of adipose tissue interspersed between myofibers occurs in obesity [189], and inflammation exerts negative effects also in skeletal muscle [199]. A thorough description of muscle IR is beyond the purpose of this paper (see [189,198] for recent reviews).

There are no studies on IR in skeletal muscle in OSA patients, but one study in mice subjected to IH for 9 hours found that glucose utilization decreased and IR

increased in oxidative (soleus) but not in glycolytic (vastus) muscles [180]. Some studies have reported a low exercise capacity in OSA patients, suggesting that OSA may impact on muscle metabolism [200].

4.2 Hepatic steatosis and nonalcoholic fatty liver disease (NAFLD)

4.2.1 Obesity

Obesity causes intracellular accumulation of lipids in the liver [187,201], leading to hepatic steatosis which is pathologically defined as presence of fat in more than 5% of hepatocytes. Activation of macrophage-like Kupffer cells in the liver is also common in obesity [202].

Hepatic steatosis is the first step of nonalcoholic fatty liver disease (NAFLD), which includes a spectrum of pathologic conditions - steatosis without inflammation, nonalcoholic steatohepatitis (NASH), and liver fibrosis [203-206]. NAFLD increases the risk of developing cryptogenic cirrhosis and hepatocarcinoma [207]. NAFLD is common in obese adults [203,204,208-211] and children [212], and is considered as the hepatic manifestation of the MetS. NAFLD could develop in steps, with IR and obesity acting as the 'first hit' and causing hepatic steatosis [205,206], and oxidative stress, lipid peroxidation and inflammation likely implicated in the 'second hit' [205-207]. Although skeletal muscle is of major importance for insulin-regulated glucose disposal, liver insulin resistance will lead to enhanced hepatic glucose production, which may significantly contribute to impaired glucose tolerance and/or hyperglycemia.

Different mechanisms have been proposed to explain the pathogenesis of NAFDL in obesity [213]. The main view considers hepatic accumulation of fat as a

consequence of obesity and IR [198]. Conversely, other studies suggested that fat accumulation in the liver may cause IR independent of visceral fat [214,215]. Finally, accumulation of triglycerides in the liver may not be detrimental per se, and could actually exert a protective role by limiting the accumulation of FFA [216].

According to the main view, the liver in obesity is loaded with excess FFA from dietary sources, adipose tissue, and de novo synthesis of lipids [201,217]. Release of FFA from the adipose tissue accounts for a large proportion of liver fat [217], and is favored by IR at the adipocyte level, since insulin normally promotes lipid storage and inhibits lipolysis and FFA release by adipocytes [218]. While FFA uptake in the liver is increased [214], their beta-oxidation is impaired [201 219]. Moreover, hyperglycemia and hyperinsulinemia enhance *de novo* lipogenesis in the liver [213]. Therefore, in very simplified terms, liver steatosis in obesity results from disturbance in several steps of FFA/lipid handling.

The cause of the transition from steatosis to steatohepatitis is incompletely defined. Inflammation is a major culprit [187,213], since liver Kupffer cells could play a role similar to that of macrophages in adipose tissue [99]. Indeed, depletion of Kupffer cells in an animal model prevented the development of IR and lipid accumulation in the liver [202].

4.2.2 OSA

The link between altered metabolism and inflammation in obesity may be amplified in OSA [220]. Increased circulating FFA have been recently reported in patients with OSA without the MetS compared to gender, age-, and BMI-matched controls [221]

and in patients with chronic heart failure and OSA during sleep [222], suggesting an effect of OSA on lipid metabolism independent of concurrent obesity.

The association of OSA and fatty liver has been recently reviewed [223]. About 50% of patients with NAFLD refer symptoms of OSA [224], and some case reports suggest that severe OSA may lead to liver injury [225-227]. Noninvasive imaging techniques, such as ultrasound or CT scans, do not currently help to distinguish between simple steatosis and NASH [228-230]. Since liver enzymes are neither sensitive nor specific predictors of NAFLD-related liver damage [207,208], data on NAFLD have been mostly obtained by liver biopsy in obese patients undergoing bariatric surgery [207,231].

In morbidly obese subjects, the degree of liver pathologic abnormalities and/or enzymes increased with OSA severity in some [232-235] but not all studies [236,237]. Table 2 summarizes the main studies on liver function in OSA patients. In subjects with OSA and elevated liver enzymes in the absence of any known liver disease, an AHI > 50 was associated with more severe hepatic steatosis, necrosis and fibrosis compared to patients with an AHI ≤50, despite similar degree of obesity [238]. Other studies reported an association of IH during sleep with NASH and liver fibrosis [232,234,239] or high serum aminotransferase levels [240]. Severity of nocturnal hypoxemia correlated with markers of liver dysfunction also in non-obese OSA patients [239]. In children, OSA was associated with elevated liver enzyme levels [241,242], which normalized after adenotonsillectomy [241]. Therefore, some clinical data support the possibility that OSA may worsen liver function.

4.2.3 Intermittent hypoxia in animal models

In mice fed a high-calorie diet, IH converted hepatic steatosis to steatohepatitis and liver fibrosis, and caused oxidative stress in the liver by up-regulating an important enzyme of oxidative stress, NADPH oxidase [243]. Similarly, exposure of rats to chemically-induced hypoxemia enhanced the development of NASH induced by high-fat diet [244]. In lean mice on regular chow diet, exposure to IH for 12 weeks caused only minor liver injury [245]. These data suggest that IH alone is insufficient to cause steatohepatitis but could amplify the damage caused by obesity.

4.3 Dyslipidemia in obesity and OSA

Obesity, the MetS and type 2 diabetes are characterized by a specific pattern of plasma lipids, called atherogenic dyslipidemia [246], which is a powerful cardiovascular risk factor [247] [248,249]. Atherogenic dyslipidemia is also common in OSA, and a role for OSA in worsening dyslipidemia is suggested by several experimental and clinical studies.

4.3.1 Obesity

The hallmarks of atherogenic dyslipidemia associated with obesity and type 2 diabetes are: high fasting levels of triglycerides (TG), total cholesterol, and cholesterol associated with very low- (VLDL) and low-density (LDL) lipoproteins, and low HDL cholesterol [247] The liver plays a central role in lipoprotein metabolism (see [250-252] for reviews). Briefly, synthesis, modification, and clearance of lipoproteins are complex processes, modulated by insulin at several steps. A major feature of obesity is the overproduction of VLDL, due to increased release of FFA by visceral adipose tissue [251].

Apolipoprotein-B (Apo-B) is an essential constituent of atherogenic particles, and its plasma level is increasingly used as a clinical marker of atherogenesis [252,253]. The size of lipoproteins is a crucial determinant of their atherogenetic potential, since small particles remain trapped in the subintimal vascular layer, where they initiate and sustain plaque formation. While the role played by small dense low-density lipoproteins (sdLDL) in atherogenesis has been known for a long time [254], recent research has examined the risk linked to remnant lipoproteins, derived from metabolism of trygliceride-rich lipoproteins (TRL) [255].

Obesity is also characterized by low levels of HDL-cholesterol, which is considered to exert protective cardiovascular effects. Decreased HDL is in part secondary to an exchange of cholesterol-triglycerides between HDL and TRL particles, which occurs when triglyceride-rich lipoprotein levels increase [251]. Hepatic and endothelial lipases have also been shown to modulate HDL levels in obesity [251].

4.3.2 OSA

The association between OSA and dyslipidemia has been explored in several studies. In a large community-based sample (Sleep Heart Health Study), OSA severity correlated with fasting total cholesterol levels independent of body mass index (BMI) [256]. In elderly subjects, OSA was associated with low HDL-cholesterol levels independent of age and BMI [257].

In a case-control study, patients with OSA had higher total and LDL cholesterol levels compared to controls matched for age, BMI and smoking status [258]. Increased

Apo-B levels have been found in adult [259] and pediatric [260] OSA patients, and Apo-B decreased after effective OSA treatment [259-261].

OSA patients show decreased levels of lipoprotein lipase [262] and pro-atherogenic dyslipidemia [141,263-265]. Severity of nocturnal hypoxemia predicted increased liver levels of stearoyl coenzyme A desaturase (SCD-1), an enzyme involved in triglyceride biosynthesis and lipopotein secretion, in obese OSA patients [232]. In contrast, other studies found similar plasma lipids in patients with OSA and controls [170,266-268]. HDL dysfunction has also been found in OSA [267]. Therefore, OSA appears associated with dyslipidemia, but data are still insufficient to confirm a causal relationship.

4.3.3 Intermittent hypoxia in animal models

In lean mice, chronic IH increased serum total cholesterol, triglycerides, VLDL-cholesterol, LDL-cholesterol, and lipid liver content [269-271] proportionally to the severity of the hypoxic stimulus [271] In obese *ob/ob* mice, chronic IH exacerbated dyslipidemia, hepatic steatosis and IR [181,269]. While isolated chronic IH was insufficient to cause atherosclerosis, it greatly potentiated the pro-atherogenic effects of a high-cholesterol diet [272].

Studies in mice have identified some steps of hepatic lipid biosynthesis which are affected by IH [213 273]. IH increases hepatic levels of the transcription factor sterol regulatory element binding protein-1 (SREBP-1) and of SCD-1 [269,270,274]. Dyslipidemia and hepatic steatosis in mice exposed to chronic IH were associated with up-regulation of SCD-1 [269-272 275], while depletion of SCD-1 reversed hyperlipidemia [274]. Thus, chronic IH may induce metabolic dysfunction via SCD-1.

The mechanisms by which IH impacts on hepatic lipid biosynthesis are poorly understood. Hypoxic activation of HIF-1α may play a role, since mice with partial deficiency of HIF-1α exposed to IH showed attenuated hyperlipidemia, IR, hepatic steatosis, and SCD-1 induction [276]. However, other pathways may also be involved. First, acute hypoxia induces lipolysis, possibly via sympathetic activation [277]. Second, hypoxia may suppress β-oxidation of fatty acids [278]. Finally, IH decreases the activity of lipoprotein lipase (LpL) in adipose tissue [279], which plays a primary role in the hydrolysis of triglycerides in circulating chilomicrons and VLDL [280,281].

As a summary of this Section, Figure 1 schematically reports the metabolic abnormalities found in visceral obesity and OSA, and highlights points of possible detrimental synergies of both conditions.

5. THE METABOLIC EFFECTS OF SLEEP LOSS

Sleep loss may play a role in the pathogenesis of obesity and metabolic abnormalities, as suggested by epidemiological and mechanistic studies [14,15]. An association of self-reported short sleep and/or sleep disruption with the MetS has been found in the general population [282-284] and shift workers [285,286]. Short sleep duration may increase the risk of incident diabetes [287,288] and stroke [289]. Some studies suggest that sleep loss may contribute to the pathogenesis of cardiovascular disease in shift workers [290-292].

Cross-sectional epidemiological data in adults and children have shown an association between obesity and self-reported short sleep duration and/or poor quality of sleep [14,293-295]. A negative linear association between baseline habitual sleep duration

and later obesity has been demonstrated by prospective longitudinal data in children [295] but not in adults [296]. However, there are no experimental data in children or adults demonstrating that shortened sleep and/or poor sleep quality are causally related to the increased prevalence of obesity. Furthermore, in mice chronic sleep restriction induced a catabolic state and weight loss despite increased feeding [297].

Reduced sleep duration (at least in the short-term) may increase the risk of weight gain by altering the regulation of appetite and by reducing insulin sensitivity [298-300]. Slow wave sleep (SWS) appears to play a protective role [301], in agreement with cross-sectional population data showing an inverse association between the amount of SWS and BMI. In addition, even a modest sleep restriction is associated with increased release of inflammatory cytokines in healthy young adults [302]. Finally, circadian rhythms are increasingly studied with special attention to the role of peripheral clock genes in obesity, diabetes and cardiovascular disease [303-307].

Little is known about the effects of sleep fragmentation, as it occurs in OSA patients, on metabolic variables. One recent study showed decreased insulin sensitivity and increased sympathetic activation in normal subjects after acute sleep fragmentation [308].

In the future, studies will need to closely examine compartment-specific adipose tissue (especially visceral fat) under conditions of sleep restriction and/or disruption. Experimental manipulation of sleep requires intensive sampling over day and night under conditions of constant routine. The role of OSA-associated sleep disruption in promoting visceral obesity is still an open question.

6. EFFECTS OF TREATMENT FOR OBESITY AND OSA

The aim of this Section is to briefly discuss some aspects of obesity and OSA with regard to treatment. In particular, the major problem of weight loss by pharmacologic treatment or bariatric surgery is addressed in obese and OSA patients, as well as the changes in metabolic variables observed after CPAP treatment.

6.1 Therapeutic strategies in obesity and the metabolic impact of weight loss

Interventions aiming at correcting visceral adipocyte dysfunction may positively modulate the clinical phenotype and cardiometabolic outcomes of MetS patients [309]. Non-pharmacological approaches, such as diet to reduce caloric intake and exercise to increase energy expenditure, are the most effective interventions to improve metabolism and prevent type 2 diabetes in individuals at risk [310,311].

Other modalities of weight loss, such as bariatric surgery or medications, may have more success in the long-term than diet alone, as summarized in a recent review [312]. Laparoscopic gastric banding in severe obesity is a safe and effective method to achieve long-term weight reduction [313-315]. The Swedish Obesity Study has shown long-term weight loss and decreased 10-year mortality in severely obese patients randomized to bariatric surgery compared to those undergoing conventional dietary treatment [316].

A comprehensive discussion of the treatment of obesity is beyond the scope of this article. It is worth noting that the development of new drugs to improve insulin sensitivity and reduce body weight is a major continuing challenge for the pharmaceutical industry. For example, drugs that improve insulin action are available (i.e., specific agonists of the PPAR-gamma nuclear receptor), but their usefulness in obese patients is limited since they may also promote weight gain [309].

Thiazolidinediones are also a class of medications with severe side effects. In addition, the development of drugs for obesity has been until now hampered by significant side effects, as recently shown by the experience with rimonabant, a selective antagonist of endocannabinoid CB1 receptor. Endocannabinoid CB1 receptors initially appeared as a good target for treatment, since they are highly expressed in regions of the brain involved in feeding and energy regulation, but also in adipose tissue, gastrointestinal tract, liver and skeletal muscle [317]. In phase-3 clinical trials, rimonabant caused weight loss and improved the metabolic profile [309], but had to be withdrawn from the market because of major psychiatric side effects [318]. Another recent target for obesity treatment is represented by the incretin system [319]. The results are promising for the treatment of obese patients, since incretin mimetics were found to reduce overall body fat with prominent effects on visceral adipose tissue [320,321].

Inflammation in visceral obesity is another potential intervention target, and salicylate derivatives are currently under intense investigation [322-325]. However, efficacy of new drugs needs to be tested not only for reduction of body weight, but also for prevention of cardiovascular events in the long term. In addition, new drugs should be specifically studied in patients of different ages, given the significant prevalence of obesity in young and old subjects [326].

6.2 Metabolic impact of CPAP treatment in OSA

CPAP intervention studies can provide information on whether specific health effects in obese patients can be modified by reversal of OSA. In general, analysis of the effects of CPAP is complicated by the variable compliance and adherence to treatment

by OSA patients. CPAP treatment does not promote weight loss [327], and did not clearly affect diabetes [328] or other metabolic disorders [37]. The majority of recent studies, including randomized controlled trials [329-331], showed no effect of CPAP treatment on metabolic variables despite improvements in sleepiness and blood pressure, as recently summarized [37,128,149,150,332,333]. However, a recent RCT in Chinese male OSA patients without significant comorbidities reported inproved insulin sensitivity in the effective CPAP group after 1 week of treatment, which was maintained at 3 months only in overweight/obese patients [184].

Circulating leptin decreased after CPAP treatment [156,334], especially in nonobese [157,335] and CPAP-compliant [336,337] patients. CPAP treatment also reversed low serum adiponectin levels in obese OSA patients [165,166], even though IR was unaffected [166]. These data are in agreement with the experimental findings that both continuous and intermittent hypoxia *in vitro* inhibit adiponectin production or secretion by adipocytes [37,89,90,114], but firm evidence is still missing, given the negative result of a RCT [331].

A similar uncertainty exists with regard to the effects of CPAP treatment on liver dysfunction. In an observational study, CPAP treatment for OSA for a single night slightly but significantly decreased serum ALT and AST levels [338]. In contrast, a randomized controlled study found no difference in liver enzymes after effective or sham CPAP treatment [339]. Whether CPAP treatment for OSA affects liver pathology, i.e. the amount of fat deposition and NAFLD severity, is currently unknown.

Several non-randomized and randomized studies have examined the effect of OSA treatment on plasma lipids. Chin and coworkers first showed that CPAP treatment decreased LDL-C and increased HDL-C levels [340,341]. Positive effects of CPAP on lipids were reported in 3 non-randomized studies [259,261,334]. A large RCT found

decreased plasma cholesterol levels after therapeu.tic but not after sub-therapeutic CPAP for one month [342]. Three other randomized studies showed no effect of CPAP, but they included small numbers of subjects [259,329,334]. Therefore, current evidence suggests that CPAP treatment may decrease total and LDL cholesterol levels. Unfortunately, none of the available studies stratified patients for obesity.

6.3 Metabolic impact of weight loss in OSA

Although changes in weight were associated with changes in OSA severity in both population and clinic-based studies [28-31], weight loss research for OSA has been hampered with doubts about the long-term effectiveness of weight loss as the only treatment in OSA. It is still unknown whether OSA patients could lose weight in the short- or long-term, and by what method this might be best achieved [343]. A recent randomized controlled trial of diet-induced weight loss for mild OSA reported positive results [344], but mild OSA may carry limited or no morbidity. In moderate-to-severe OSA, a therapeutic approach combining CPAP with diet to reduce weight might be more appropriate, as suggested by two recent RCT in obese diabetic [345] or nondiabetic [346] OSA patients. Data after 1-year follow-up suggest that long-term maintenance of weight after initial very low energy diet in obese OSA patients is associated with persistent improvement of OSA [347]. Other studies reported less optimistic results after a 2-year follow-up [348].

Bariatric surgery has also been used in OSA patients. In the Swedish Obesity Study cohort, prevalence of OSA-related symptoms at 2-year follow-up decreased proportionally to weight loss [349]. According to a 2004 meta-analysis, OSA resolved in

85% of the patients after bariatric surgery [349], as confirmed by studies including polysomnographic assessment [350-352].

As for use of medications to treat obesity, the effects of sibutramine have been recently assessed in obese OSA patients. Sibutramine did not affect sleep [353], and weight loss was associated with improved AHI and daytime sleepiness over a 6-month period [354]. The metabolic profile improved in obese OSA patients treated with sibutramine, low-calorie diet and exercise for 6 months [355]. Another study compared the effects of sibutramine to those of CPAP in patients who had been allowed to choose between the two treatments [356]. Sibutramine treatment caused a 5-kg weight loss over one year and positively modified oxygen saturation during sleep, but did not affect AHI or cardiovascular variables. Conversely, CPAP-treated patients improved their respiratory variables during sleep and daytime blood pressure but did not lose weight [356]. Unfortunately, the results of these studies are not going to impact on the clinical management of OSA patients, since in early 2010 sibutramine has been withdrawn in Europe due to increased cardiovascular events associated with prolonged administration of the drug [357].

Overall, these studies underline the need for individualized treatment of obesity in OSA patients. Life-long adherence to CPAP treatment is a problem in OSA treatment [358], justifying additional pharmacologic approaches. It is likely that OSA treatment and metabolic risk management, possibly integrated in the same sleep center, may be necessary to obtain optimal results, but evidence-based management strategies are still missing.

7. OBESITY AND OSA IN CHILDREN

Obesity and the MetS in children have been increasingly studied in the last decade. More than genetic defects, sedentary lifestyle and unhealthy food habits are considered the main culprits of pediatric obesity [359] and the rising prevalence of type 2 diabetes in the young population [360]. Clinically, the immediate and long-term effects of childhood obesity are strikingky similar to those of adult obesity (reviewed in [359]). There is evidence that cardiovascular lesions develop in obese children [361], raising concerns about the long-term impact of childhood obesity on health.

Prevalence of OSA in children is expected to increase due to the rise in obesity [18,19 20]. Besides its immediate effects (snoring, daytime symptoms), pediatric OSA may influence the natural history of sleep disordered breathing in adulthood [362], including metabolic dysfunction. However, not every child with OSA will manifest adverse consequences, suggesting modulation by genetic and environmental factors [363].

OSA and obesity likely interact at the level of upper airways. Obese children with OSA showed a larger size of tonsils and adenoids compared to controls [364,365], and a higher risk of residual OSA after adenotonsillectomy [364,366]. On the other hand, upper airway closure may occur in obese children for a smaller degree of tonsil and adenoid enlargement than in non-obese children [364]. The relative contribution of (central) obesity and adenotonsillar hypertrophy remains to be elucidated and may differ between young children, in whom adenotonsillar hypertrophy might play a major role, and adolescents, who show a predominant role of obesity [367]. Recent studies have tried to address the impact of fat distribution and neck anatomy in a case-control study of obese children with and without OSA [368], but more studies are needed before drawing any conclusion on this topic. It should be pointed out that hereditable factors influencing

craniofacial structures represent important predisposing conditions to develop upper airway obstruction, together with the acquired factors of adenotonsillar hypertrophy and obesity [369].

Similar to adults, obese children and adolescents often develop the MetS [370 371 372-374], which appears linked to visceral obesity and ectopic fat deposition [375], secondary to excess caloric intake and reduced physical activity. While obesity is known to increase the risk for OSA, it is unclear whether OSA in children is directly involved in the pathogenesis of the MetS. Differently from adults, the pediatric population is relatively free from prolonged exposure to cardiometabolic risk factors, and childhood OSA causes a lesser degree of oxygen desaturation than adult OSA, resulting in milder intermittent hypoxemia compared to adult patients. OSA-associated nocturnal hypoxemia in children independently predicted the MetS and glucose intolerance [376-378], and prevalence of the MetS increased with increasing severity of OSA [379-381], together with markers of inflammation [381], arterial alterations [382], and excessive daytime sleepiness [381,383]. In non-obese children, HDL-cholesterol level was recently found to be inversely correlated with OSA severity [384] Conversely, other studies suggested that IR in children with OSA is associated with obesity rather than with OSA [385-387].

A similar degree of uncertainty regards liver dysfunction. Two studies reported increased elevated serum aminotransferase levels in obese children with OSA, suggesting that OSA could act as a "second hit" in the development of NAFLD in children [241,242]. Increased leptin levels have been reported in children with OSA, in the absence of changes in either adiponectin or resistin [388]. Other studies suggested that adiponectin is a sensitive marker of OSA in obese pubertal children [386] or found a predominant effect of obesity on adipokine levels [389]. The exact pathogenesis and long-

term consequences of early perturbations in metabolism by pediatric OSA warrant urgent research efforts.

7.1 Effects of treatment of pediatric OSA

Therapeutic interventions in children should be aimed at correcting both sleep apnea and concomitant obesity if present. There is no agreement on the criteria to define the success rate of treatment in pediatric OSA, making it hard to compare the results of available studies [390].

The results of adenotonsillectomy (AT) have been conflicting. AT carries a low success rate [25]. In addition, BMI often increases post-operatively, due to increased appetite, decreased nocturnal energy expenditure, and decreased total motor activity [391]. One study using a pre-/post surgery design to assess the effect of OSA on IR in non-obese and obese children found that OSA was clearly associated with IR in obese children only; plasma lipids markedly decrease in obese patients with resolution of OSA, while they showed a minor improvement in patients with residual OSA post-surgery [260]. In another study, lipid profiles, CRP, and Apo-lipoprotein B significantly improved after adenotonsillectomy in both obese and non-obese children [388]. Other studies failed to show any effect of AT on fasting insulin or the HOMA index, or found that the metabolic profile worsened after surgery due to increased BMI [392], or were insufficiently powered to detect differences between subsets of obese children after surgery [393]. As for liver dysfunction, serum aminotransferase levels decreased in the majority of obese OSA children after adenotonsillectomy [241], but further study is needed to confirm a cause-effect relationship between OSA and NAFLD [394].

Experience with CPAP in children is limited, and the problem of long-term compliance to treatment may be as crucial as in adults. A single study in children found a slight decrease in leptin after CPAP treatment, while insulin sensitivity, BMI or norepinephrine levels were unaffected [395]. Weight loss is a promising alternative [390], but long-term compliance to weight loss is a relevant problem also in children.

8. FUTURE RESEARCH DIRECTIONS

Several important areas can be identified for future research. We have started to understand some mechanisms by which OSA may worsen metabolism, and studies in mice have provided a large amount of data on the effects of chronic IH. However, the effects of decreased or disrupted sleep on metabolism remain incompletely defined in both obesity and OSA. Interestingly, sleep loss may not only promote weight gain, but could also diminish fat loss during low-calorie diet, as recently found in obese humans [298].

Studies on the effects of hypoxia on adipocyte function face some methodological problem, since *in vitro* exposure to room air actually represents a condition of hyperoxia compared to the value of tissue pO_2 measured in live animals [113,114] and humans [111]. Testing the effects of IH *in vitro* on adipose tissue is problematic, due to the technical difficulty of controlling the rate of gas diffusion in cell cultures. This problem can be partly overcome by reducing the number of IH cycles per minute, in order to obtain measurable oscillations in O_2 levels in the supernatant to which the cells are exposed.

Knowledge on adipose tissue function in OSA patients is still insufficient, and the biology of adipocytes from different fat depots (visceral, subcutaneous) in obese and non-obese OSA patients has not been studied. The pattern of adipokines in OSA is incompletely defined, as well as their interaction with inflammation, which plays such an important role in both OSA and obesity.

The role of OSA and obesity in causing metabolic abnormalities in children is incompletely understood. Given the partial success of adenotonsillectomy, sleep studies and metabolic assessment should be performed in children after surgery in order to evaluate the need for further treatment. Randomized controlled studies are needed to identify the best therapeutic strategy in pediatric OSA according to the specific OSA phenotype. In addition, longitudinal studies to explore the long-term consequences of OSA in children are warranted.

A comprehensive approach, aimed at abolishing OSA but also at attaining long-term reduction in body weight, is desirable in both adults and children with OSA. In patients undergoing bariatric surgery, resolution or improvement of obesity improved OSA, especially in men. However, patients undergoing bariatric surgery may not be representative of the whole OSA population because of usual predominance of morbidly obese females. Bariatric surgery has provided important data on liver function in OSA, and remains a good opportunity for metabolic studies at the time of the intervention. Moreover, liver biopsies are easily obtained at the time of bariatric surgery, but collecting them during follow-up or in patients treated with CPAP is ethically problematic. Hopefully, improved noninvasive means of diagnosis of NAFLD will help to improve liver assessment in OSA patients.

From a clinical point of view, new models of integrated care, possibly in the same center, are needed for treatment of obese OSA patients. A multidisciplinary approach seems necessary for both adult and pediatric patients in order to provide effective treatment and prevent metabolic and cardiovascular consequences of both obesity and OSA.

References

1. Jensen MK, Chiuve SE, Rimm EB, Dethlefsen C, Tiønneland A, Joensen AM, Overvad K. Obesity, behavioral lifestyle factors, and risk of acute coronary events. *Circulation* 2008;117:3062-3069.

2. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. *Nat Rev Cardiol* 2009;6:399-409.

3. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. *N Engl J Med* 2008;359:2105-2120.

4. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. *J Am Med Assoc* 2008;299:2401-2405.

5. Jackson-Leach R, Lobstein T. Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. *Int J Pediatr Obes* 2006;1:26-32.

6. Steinberger J, Moran A, Hong CP, Jacobs DRJ, Sinaiko AR. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. *J Pediatr* 2001;138:469-473.

7. Cali AMG, Caprio S. Obesity in children and adolescents. *J Clin Endocrinol Metab* 2008;93:s31-36.

8. Trayhurn P, Wood S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. *Br J Nutr* 2004;92:347-355.

9. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 2006;444:860-867.

10. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. *Nat Rev Immunol* 2008;8:923-934.

11. Einstein FH, Atzmon G, Yang XM, Ma XH, Rincon M, Rudin E, Muzumdar R, Barzillai N. Differential responses of visceral and subcutaneous fat depots to nutrients. *Diabetes* 2005;54:672-678.

12. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? *Br J Nutr* 2008;100:227-235.

13. Yang L, Hotamisligil GS. Stressing the brain, fattening the body. *Cell* 2008;135:20-22.

14. Cappuccio FP, Taggart FM, Kandala NB, Currie A, Peile E, Stranges S, Miller MA. Meta-analysis of short sleep duration and obesity in children and adults. *Sleep* 2008;31:619-626.

15. Marshall NS, Glozier N, Grunstein RR. Is sleep duration related to obesity? A critical review of the epidemiological evidence. *Sleep Med Rev* 2008;12:289-298.

16. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl Physiol* 2005;99:1592-1599.

17. Li C, Ford ES, Zhao G, Croft JB, Balluz LS, Mokdad AH. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005–2006. *Prev Med* 2010;51:18-23.

18. Kaditis AG, Alexopoulos EI, Hatzi F, Karadonta I, Chaidas K, Gourgoulianis K, Zintzaras E, Syrogiannopoulos GA. Adiposity in relation to age as predictor of severity of sleep apnea in children with snoring. *Sleep Breath* 2008;12:25-31.

19. Tauman R, Gozal D. Obesity and obstructive sleep apnea in children. *Paediatr Respir Rev* 2006;7:247-259.

20. Redline S, Tishler PV, Schluchter M, Aylor J, Clark K, Graham G. Risk factors for sleep-disordered breathing in children. Association with obesity, race, and respiratory problems. *Am J Respir Crit Care Med* 1999;159:1527-1532.

21. Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. *Proc Am Thorac Soc* 2008;5:144-153.

22. Levy P, Pepin JL, Arnaud C, Tamisier R, Borel JC, Dematteis M, Godin-Ribuot D, Ribuot C. Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. *Eur Respir J* 2008;32:1082-1095.

23. Bianchi MT, Cash SS, Mietus J, Peng C-K, Thomas R. Obstructive sleep apnea alters sleep stage transition dynamics. *PLoS ONE* 2010;5:e11356.

24. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment

with continuous positive airway pressure: an observational study. *Lancet* 2005;365:1046-1053.

25. Costa DJ, Mitchell R. Adenotonsillectomy for obstructive sleep apnea in obese children: a meta-analysis. *Otolaryngol Head Neck Surg* 2009;140:455-460.

26. Bhattacharjee R, Kheirandish-Gozal L, Mitchell RB, Promchiarak J, Simakajornboon N, Kaditis AG, Splaingard D, Splaingard M, Brooks LJ, Marcus CL, Sin S, Arens R, Verhulst SL, Gozal D. Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children.
A multicenter retrospective study. *Am J Respir Crit Care Med* 2010;182:676-683.

27. Phillips BG, Hisel TM, Kato M, Pesek CA, Dyken ME, Narkiewicz K, Somers VK. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. *J Hypertens* 1999;17:1297-1300.

28. Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of sleep-disordered breathing with changes in weight. *Arch Intern Med* 2005;165:2408-2413.

29. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. *J Am Med Assoc* 2000;284:3015–3021.

30. Grunstein RR, Wilcox I, Yang TS, Gould Y, Hedner J. Snoring and sleep apnoea in men: association with central obesity and hypertension. *Int J Obes Relat Metab Disord* 1993;17:533-540.

31. Welch KC, Foster GD, Ritter CT, Wadden TA, Arens R, Maislin G, Schwab RJ. A novel volumetric magnetic resonance imaging paradigm to study upper airway anatomy. *Sleep 2002*;25:532-542.

32. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Maruyama N, Morioka K, Nakatani K, Yano Y, Adachi Y. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. *Diabetes Care* 2003;26:2341-2344.

33. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. *Gend Med* 2009;6:60-75.

34. Sans Capdevila O, Kheirandish-Gozal L, Dayyat E, Gozal D. Pediatric obstructive sleep apnea: Complications, management, and long-term outcomes. *Proc Am Thorac Soc* 2008;5:274-282.

35. Bonuck K, Parikh S, Bassila M. Growth failure and sleep disordered breathing: A review of the literature. *Int J Pediatr Otorhinolaryngol* 2006;70:769-778.

36. Bonsignore MR, Eckel J. Metabolic aspects of obstructive sleep apnoea syndrome. *Eur Respir Rev* 2009;18:113-124.

37. Lévy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. *Eur Respir J* 2009;34:243-260.

38. Yin J, Gao Z, He Q, Zhou D, Guo ZK, Ye J. Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. *Am J Physiol Endocrinol Metab* 2009;296:E333-E342.

39. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. *Eur Respir J* 2009;33:1467-1484.

40. Wolk R, Somers VK. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. *Diabetes Obes Metab* 2006;8:250-260.

41. Kent BD, Ryan S, McNicholas WT. The genetics of obstructive sleep apnoea. *Curr Opin Pulm Med* 2010;16:536-542.

42. Riha RL. Genetic aspects of the obstructive sleep apnoea/hypopnoea syndrome--is there a common link with obesity? *Respiration* 2009;78:5-17.

43. Riha RL, Gislasson T, Diefenbach K. The phenotype and genotype of adult obstructive sleep apnoea/hypopnoea syndrome. *Eur Respir J* 2009;33:646–655.

44. Lee D-E, Kehlenbrik S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. *Am J Physiol Endocrinol Metab* 2009;296:1210-1229.

45. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. *Nature* 2006;444:847-853.

46. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines: energy regulation from the human perspective. *J Nutr* 2006;136 1935S-1939S.

47. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nature Rev Immunol* 2011;11:85-97.

48. DiGirolamo M, Fine JB, Tagra K, Rossmanith R. Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. *Am J Physiol Regul Integr Comp Physiol* 1998;274:R1460-1467.

49. Garaulet M, Hernandez-Morante JJ, Lujan J, Tebar FJ, Zamora S. Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans. *Int J Obes* 2006;30:899-905.

50. Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, Cushman SW, Periwal V. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. *PLoS Comput Biol* 2009;5:e1000324.

51. Bowers RR, Festuccia WT, Song CK, Shi H, Migliorini RH, Bartness TJ. Sympathetic innervation of white adipose tissue and its regulation of fat cell number. *Am J Physiol Regul Integr Comp Physiol* 2004;286:R1167-R1175.

52. Guo K, Mogen J, Struzzi S, Zhang Y. Preadipocyte transplantation: an in vivo study of direct leptin signaling on adipocyte morphogenesis and cell size. *Am J Physiol Regul Integr Comp Physiol* 2009;296:R1339-1347.

53. Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, Stumvoll M, Bluher M. Insulin-sensitive obesity. *Am J Physiol Endocrinol Metab* 2010;299:E506-515.

54. Cinti S. Transdifferentiation properties of adipocytes. *Am J Physiol Endocrinol Metab* 2009;297:E977-E986.

55. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. *Am J Physiol Endocrinol Metab* 2007;293:E444-E452.

56. Stephens M, Ludgate M, Rees A. Brown fat ald obesity: the next big thing? *Clin Endocrinol* 2011;74:661-670.

57. Taksali SE, Caprio S, Dziura J, Dufour S, Cali AM, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. *Diabetes* 2008;57:367-371.

58. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation* 2003;108:414–419.

59. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. *Lancet* 2005;366:1059–1062.

60. Bays HE, Gonzales-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Pathogenic potential of adipose tissue and metabolic

consequences of adipocyte hypertrophy and increased visceral adiposity. *Expert Rev Cardiovasc Ther* 2008;6:343-368.

61. Walker GE, Verti B, Marzullo P, Savia G, Mencarelli M, Zurleni F, Liuzzi A, Di Blasio AM. Deep subcutaneous adipose tissue: a distinct abdominal adipose depot. *Obesity* 2007;15:1933-1943.

62. Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. *J Cell Mol Med* 2010;14:2223-2234.

63. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735-2752.

64. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010;53:600-605.

65. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? *J Clin Endocrinol Metab* 2004;89:2569-2575.

66. Meigs JB, Wilson PWF, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB. Body Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease. *J Clin Endocrinol Metab* 2006;91:2906-2912.

67. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. *Int J Obes* 2010;34:949-959.

68. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. *J Clin Endocrinol Metab* 2008;93:S57-S63.

69. Lin J-W, Caffrey JL, Chang M-H, Lin Y-S. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality—Cohort analysis from the Third National Health and Nutrition Examination Survey. *J Clin Endocrinol Metab* 2010;95:4258-4267.

70. Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P. Metabolically healthy obesity: different prevalences using different criteria. *Eur J Clin Nutr* 2010;64:1043-1051.

71. Perrini S, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Natalicchio A, Orlando MR, Garruti G, De Fazio M, Catalano G, Memeo V, Giorgino R, Giorgino F. Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. *Diabetologia* 2008;51:155-164.

72. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143-147.

73. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. *Acta Physiol Scand* 2005;183:13-30.

74. Ktotkiewski M, Sjostrom L, Bjorntorp P, Smith U. Regional adipose tissue cellularity in relation to metabolism in young and middle-aged women. *Metabolism* 1975;24:703-710.

75. Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity *Am J Physiol Endocrinol Metab* 2007;293:E656-E665.

76. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. *Ann NeW York Acad Sci* 2010;1212:E1-E19.

77. Myers MGJ, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. *Trends Endocrinol Met* 2010;21:643-651.

78. Kanasaki K, Koya D. Biology of obesity: lessons from animal models of obesity. *J Biomed Biotechnol* 2011;2011:197636.

79. Malli F, Papaioannou AI, Gourgoulianis KI, Daniil Z. The role of leptin in the respiratory system: an overview. *Respir Res* 2010;11:152.

80. Ambrosini G, Nath AK, Sierra-Honigmann MR, Flores-Riveros J. Transcriptional activation of the human leptin gene in response to hypoxia. *J Biol Chem* 2002;277:34601-34609.

81. Matarese G, Procaccini C, De Rosa V, Horvath TL, La Cava A. Regulatory T cells in obesity: the leptin connection. *Trends Mol Med* 2010;16:247-256.

82. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. *Circulation* 2008;117:3238-3249.

83. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. *J Biol Chem* 2006;281:2654-2660.

84. Han SH, Sakuma I, Shin EK, Koh KK. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. *Prog Cardiovasc Dis* 2009;52:126-140.

85. Esteve E, Ricart W, Fernandez-Real JM. Adipocytokines and insulin resistance. *Diabetes Care* 2009;32:S362-S367.

86. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. *Mol Cell Endocrinol* 2004;219:9-15.

87. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H, Saito I. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. *J Atheroscler Thromb* 2010;17:1201-1211.

88. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2002;290:1084-1089.

89. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. *Biochem Biophys Res Commun* 2006;341:549-556.

90. Magalang UJ, Cruff JP, Rajappan R, Hunter MG, Patel T, Marsh CB, Raman SV, Parinandi NL. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. *Exp Clin Endocrinol Diabetes* 2009;117:129-134.

91. Han SH, Quon MJ, Kim J. Adiponectin and cardiovascular disease: response to therapeutic interventions. *J Am Coll Cardiol* 2007;49:531-538.

92. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* 1993;259:87-91.

93. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest* 2006;116:1793-1801.

94. Zeyda M, Stulnig TM. Adipose tissue macrophages. *Immunology Letters* 2007;112:61–67.

95. Solinas G, Karin M. JNK1 and IKK-beta : molecular links between obesity and metabolic dysfunction. *FASEB J* 2010;24:2596-2611.

96. Anand RJ, Gribar SC, Li J, Kohler JW, Branca MF, Dubowski T, Sodhi CP, Hackam DJ. Hypoxia causes an increase in phagocytosis by macrophages in a HIF-1alpha-dependent manner. *J Leukoc Biol* 2007;82:1257-1265.

97. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Amstrup Pedersen A, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. *J Biol Chem* 2010;285:6153-6160.

98. Barbatelli MC, Pairsani V, Latini C, Muzzonigro G, Castellucci M, Cinti S. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. *J Lipid Res* 2008;49:1562-1568.

99. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest* 2007;117:175-184.

100. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O'Brien PE, Harrison LC. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. *Diabetes* 2010;59:1648-1656.

101. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action and insulin resistance. *Am J Physiol Endocrinol Metab* 2009;296:E581-E-591.

102. Varlamov O, Somwar R, Cornea A, Kievit P, Grove KL, Roberts CT, Jr. Single-cell analysis of insulin-regulated fatty acid uptake in adipocytes. *Am J Physiol Endocrinol Metab* 2010;299:E486-496.

103. O'Connell J, Lynch L, Cawood TJ, Kwasnik A, Nolan N, Geoghegan J, McCormick A, O'Farrelly C, O'Shea D. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. *PLoS One* 2010;5:e9997.

104. Maumus M, Sengenes C, Decaunes P, Zakaroff-Girard A, Bourlier V, Lafontan M, Galitzky J, Bouloumie A. Evidence of in situ proliferation of adult adipose tissue-derived progenitor cells: influence of fat mass microenvironment and growth. *J Clin Endocrinol Metab* 2008;93:4098-4106.

105. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. *Int J Obes (Lond)* 2008;32 Suppl 7:S52-54.

106. Gao C-L, Zhua C, Zhao Y-P, Chen X-H, Ji C-B, Zhang C-M, Zhu J-G, Xi Z-K, Tong M-L, Guo X-R. Mitochondrial dysfunction is induced by high levels of glucose and free fatty acids in 3T3-L1 adipocytes. *Mol Cell Endocrinol* 2010;329:25-33.

107. Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling role of white adipose tissue. *Arch Physiol Biochem* 2008;114:267-276.

108. Regazzetti C, Peraldi P, Grémeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti J-F, Giorgetti-Peraldi S. Hypoxia decreases insulin signaling pathways in adipocytes. *Diabetes* 2009;58:95-103.

109. Copps KD, White MF. Breathing room: the (un)natural history of adipose microhypoxia and insulin resistance. *Diabetes* 2009;58:26-27.

110. Pasarica M, Rood J, Ravussin E, Schwarz J-M, Smith SR, Redman LM. Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis. *J Clin Endocrinol Metab* 2010;95:4052-4055.

111. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. *Diabetes* 2009;58:718-725.

112. Dimitriadis G, Lambadiari V, Mitrou P, Maratou E, Boutati E, Panagiotakos DB, Economopoulos T, Raptis SA. Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. *Diabetes Care* 2007;30:3128-3130.

113. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. *Diabetes* 2007;56:901-911.

114. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. *Am J Physiol Endocrinol Metab* 2007;293:E1118-E1128.

115. Wang B, Wood S, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. *Pflugers Arch* 2007;455:479-492.

116. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. *J Biol Chem* 2003;278:19575-19578.

117. Wood IS, Wang B, Lorente-Cebrián S, Trayhurn P. Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-D-glucose uptake in human adipocytes. *Biochem Biophys Res Commun* 2007;361:468-473.

118. Pérez de Heredia F, Wood IS, Trayhurn P. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2 and MCT4) expression inhuman adipocytes. *Pflugers Arch* 2010;459:509-518.

119. Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. *J Endocrinol* 2008;198:127-134.

120. Trayhurn P, Duncan JS, Wood AM, Beattie JH. Metallothionein gene expression and secretion in white adipose tissue. *Am J Physiol Regul Integr Comp Physiol* 2000;279:R2329-R2335.
.

121. Zhang X, Lam KS, Ye H, Chung SK, Zhou M, Wang Y, Xu A. Adipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in mice. *J Biol Chem* 2010;285:32869-32877.

122. Almendros I, Farré R, Planas AM, Torres M, Bonsignore M, Navajas D, Montserrat J. Tissue oxygenation in brain, muscle and fat in a rat model of sleep apnea: differential effect of obstructive apneas and intermittent hypoxia. . *Sleep* 2011;in press.

123. Nunemaker GS, Chen M, Pei H, Kimble SD, Keller SR, Carter JD, Yang ZY, Smith KM, Wu R, Bevard MH, Garmey JC, Nadler JL. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by western diet. *Am J Physiol Endocrinol Metab* 2008;295:E1065-E1075.

124. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-Lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. *Obesity* 2009;17:1657-1663.

125. Wen YW, Gu J, Vandenhoff GE, Liu X, Nadler JL. Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. *Am J Physiol Heart Circ Physiol* 2008;294:H1933-H1938.

126. Zarrouki B, Soares AF, Guichardant M, Lagarde M, Gèloën A. The lipid peroxidation end-product 4-HNE induces COX-2 expression through p38MAPK activation in 3T3-L1 adipose cell. *FEBS Letters* 2007;581:2394-2400.

127. Singh PS, Niemczyk M, Saini D, Awasthi YC, Zimniak L, Zimniak P. Role of electrophilic lipid peroxidation product 4-hydroxynonenal in the development of obesity in mice. *Biochemistry* 2008;47:3900-3911.

128. Lui MMS, Ip MSM. Disorders of glucose metabolism in sleep-disordered breathing. *Clinics in Chest Medicine* 2010;31:271-285.

129. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. *Chest* 2005;127:2076-2084

130. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. *Am J Respir Crit Care Med* 2007;176:1274-1280.

131. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. *Sleep* 2008;31:1079-1085.

132. Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, Stubbs R, Hla KM. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep 2008* 31:1071-1078.

133. Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O'Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM. Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med* 2009;6:e1000132.

134. Mortimore IL, Marshall I, Wraith PK, Sellar RJ, Douglas NJ. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. *Am J Respir Crit Care Med* 1998;157:280-283.

135. Kawaguchi Y, Fukumoto S, Inaba M, Koyama H, Shoji T, Shoji S, Nishizawa Y. Different impacts of neck circumference and visceral obesity on the severity of obstructive sleep apnea syndrome. *Obesity* 2011;19:276-282.

136. Preis SR, Massaro JM, Hoffmann U, D'Agostino RB, Sr., Levy D, Robins SJ, Meigs JB, Vasan RS, O'Donnell CJ, Fox CS. Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. *J Clin Endocrinol Metab* 2010;95:3701-3710.

137. Onat A, Hergenç G, Yüksel H, Can G, Ayhan E, Kaya Z, Dursunoglu D. Neck circumference as a measure of central obesity: Associations with metabolic syndrome and obstructive sleep apnea syndrome beyond waist circumference. *Clin Nutr* 2009;28:46-51.

138. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino Sr RB, O'Donnell CJ, Fox CS. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study. *Obesity (Silver Spring)* 2011;18:2191-2198.

139. Ip MSM, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. *Am J Respir Crit Care Med* 2002;165:670-676.

140. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. *Am J Respir Crit Care Med* 2002;165:677-682.

141. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *Eur Heart J* 2004;25:735-741.

142. Drager LF, Lopes HF, Maki-Nunes C, Trombetta IC, Toschi-Dias E, Alves MJ, Fraga RF, Jun JC, Negrão CE, Krieger EM, Polotsky VY, Lorenzi-Filho G. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. *PLoS One* 2010;5:e12065.

143. Gasa M, Salord N, Fortuna AM, Mayos M, Vilarrasa N, Dorca J, Montserrat JM, Bonsignore MR, Monasterio C. Obstructive sleep apnoea and metabolic impairment in severe obesity. *Eur Respir J* 2011;in press.

144. Louis M, Punjabi NM. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. *J Appl Physiol* 2009;106:1538-1544.

145. Pamidi S, Aronsohn RS, Tasali E. Obstructive sleep apnea: role in the risk and severity of diabetes. *Best Pract Res Clin Endocrinol Metab* 2010;24:703-715.

146. Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. *Thorax* 1998;53:S25-S28.

147. Punjabi NM, Participants W. Do sleep disorders and associated treatments impact glucose metabolism? . *Drugs* 2009;69:13-27.

148. Vgontzas AN. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? *Arch Physiol Biochem* 2008;114:211-223.

149. Tasali E, Ip MSM. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. *Proc Am Thorac Soc* 2008;5:207-217.

150. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. *J Appl Physiol* 2005;99:1998-2007.

151. Pallayova M, Donic V, Tomori Z. Beneficial effects of severe sleep apnea therapy on nocturnal glucose control in persons with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2008;81:e8-e11.

152. Dawson A, Abel SL, Loving RT, Dailey G, Shadan FF, Cronin JW, Kripke DF, Kline LE. CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic
control during sleep. *J Clin Sleep Med* 2008;15:538-542.

153. Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. *Am J Respir Crit Care Med* 2010;181:507-513.

154. Papanas N, Steiropoulos P, Nena E, Tzouvelekis A, Maltezos E, Trakada G, Bouros D. HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men. *Vasc Health Risk Manag* 2009;5:751-756.

155. Drager LF, Queiroz EL, Lopes HF, Genta PR, Krieger EM, Lorenzi-Filho G. Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecutive patients with the metabolic syndrome. *J Cardiometab Syndr* 2009;4:89-95.

156. Ip MS, Lam KS, Ho C, Tsang KW, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. *Chest* 2000;118:580-586.

157. Harsch IA, Konturek PC, Koebnick C, Kuehnlein PP, Fuchs FS, Pour Schahin S, Wiest GH, Hahn EG, Lohmann T, Ficker JH. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. *Eur Respir J* 2003;22:251-257.

158. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, Kales A, Chrousos GP. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. *J Clin Endocrinol Metab* 2000;85:1151-1158.

159. Ozturk L, Unal M, Tamer L, Celikoglu F. The association of the severity of obstructive sleep apnea with plasma leptin levels. *Arch Otolaryngol Head Neck Surg* 2003;129:538-540.

160. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Kuriyama T. Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome. *Chest* 2005;127:716-721.

161. Schafer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, Berthold HK. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. *Chest* 2002;122:829-839.

162. Patel SR, Palmer LJ, Larkin EK, Jenny NS, White DP, Redline S. Relationship between obstructive sleep apnea and diurnal leptin rhythms. *Sleep* 2004;27:235-239.

163. Shimura R, Tatsumi K, Nakamura A, Kasahara Y, Tanabe N, Takiguchi Y, Kuriyama T. Fat accumulation, leptin, and hypercapnia in obstructive sleep apnea-hypopnea syndrome. *Chest* 2005;127:543-549.

164. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. *Sleep Med* 2007;8:12-17.

165. Nakagawa Y, Kishida K, Kihara S, Sonoda M, Hirata A, Yasui A, Nishizawa H, Nakamura T, Yoshida R, Shimomura I, Funahashi T. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. *Am J Physiol Endocrinol Metab* 2008;294:E778-E784.

166. Carneiro G, Togeiro SM, Ribeiro-Filho FF, Truksinas E, Ribeiro AB, Zanella MT, Tufik S. Continuous positive airway pressure therapy improves hypoadiponectinemia in severe obese men with obstructive sleep apnea without changes in insulin resistance. *Metab Syndr Relat Disord* 2009;7:537-542.

167. Kanbay A, Kokturk O, Ciftci TU, Tavil Y, Bukan N. Comparison of serum adiponectin and tumor necrosis factor-alpha levels between patients with and without obstructive sleep apnea syndrome. *Respiration* 2008;76:324-330.

168. Makino S, Handa H, Suzukawa K, Fujiwara M, Nakamura M, Muraoka S, Takasago I, Tanaka Y, Hashimoto K, Sugimoto T. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. *Clin Endocrinol (Oxf)* 2006;64:12-19.

169. Nakagawa Y, Kishida K, Kihara S, Yoshida R, Funahashi T, Shimomura I. Nocturnal falls and adiponectin levels in sleep apnea with abdominal obesity and impact of hypoxia-induced dysregulated adiponectin production in obese murine mesenteric adipose tissue. *J Atheroscler Thromb* 2011;18:240-247.

170. Drager LF, Bortolotto LA, Maki-Nunes C, Trombetta IC, Alves MJ, Fraga RF, Negrao CE, Krieger EM, Lorenzi-Filho G. The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome. *Atherosclerosis* 2010;208:490-495.

171. Trombetta IC, Somers VK, Maki-Nunes C, Drager LF, Toschi-Dias E, Alves MJ, Fraga RF, Rondon MU, Bechara MG, Lorenzi-Filho G, Negrão CE. Consequences

of comorbid sleep apnea in the metabolic syndrome -implications for cardiovascular risk. *Sleep* 2010;33:1193-1199.

172. Drager LF, Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, Lorenzi-Filho G. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. *Am J Cardiol* 2010;105:1135-1139.

173. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. *Sleep Med Rev* 2005;9:211-224.

174. Barcelo A, Barbe F, de la Pena M, Martinez P, Soriano JB, Pierola J, Agusti AG. Insulin resistance and daytime sleepiness in patients with sleep apnoea. *Thorax* 2008;63:946-950.

175. Nena E, Steiropoulos P, Papanas N, Tsara V, Fitili C, Froudarakis ME, Maltezos E, Bouros D. Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. *Sleep Breath* 2011;in press.

176. Ronksley PE, Hemmelgarn BR, Heitman SJ, Hanly PJ, Faris PD, Quan H, Tsai WH. Obstructive sleep apnoea is associated with diabetes in sleepy subjects. *Thorax* 2009;64:834-839.

177. Jun J, Polotsky VY. Sleep disordered breathing and metabolic effects: Evidence from animal models. *Sleep Med Clin* 2007;2:263-277.

178. Polotsky VY, Rubin AE, Balbir A, Dean T, Smith PL, Schwartz AR, O'Donnell CP. Intermittent hypoxia causes REM sleep deficits and decreases EEG delta power in NREM sleep in the C57BL/6J mouse. *Sleep Med* 2006;7:7-16.

179. Farre R, Nacher M, Serrano-Mollar A, Galdiz JB, Alvarez FJ, Navajas D, Montserrat JM. Rat model of chronic recurrent airway obstructions to study the sleep apnea syndrome. *Sleep* 2007;30:930-933.

180. Iiyori N, Alonso LC, Li J, Sanders MH, Garcia-Ocana A, O'Doherty RM, Polotsky VY, O'Donnell CP. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. *Am J Respir Crit Care Med* 2007;175:851-857.

181. Polotsky VY, Li J, Punjabi NM, Rubin AE, Smith PL, Schwartz AR, O'Donnell CP. Intermittent hypoxia increases insulin resistance in genetically obese mice. *J Physiol* 2003;552:253-264.

182. Xu J, Long YS, Gozal D, Epstein PN. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. *Free Radic Biol Med* 2009;46:783-790.

183. Yokoe T, Alonso LC, Romano LC, Rosa TC, O'Doherty RM, Garcia-Ocana A, Minoguchi K, O'Donnell CP. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic beta-cell replication in mice. *J Physiol* 2008;586:899-911.

184. Lam JCM, Lam B, Yao TJ, Lai AYK, Ooi CG, Tam S, Lam KSL, Ip MSM. A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. *Eur Respir J* 2010;35:138-145.

185. Harsch IA, Schahin SP, Radespiel-Troger M, Weintz O, Jahreiss H, Fuchs FS, Wiest GH, Hahn EG, Lohmann T, Konturek PC, Ficker JH. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. *Am J Respir Crit Care Med* 2004;169:156-162.

186. Khan SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 1996;444:840-846.

187. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. *J Clin Invest* 2008;118:2992-3002.

188. Sell H, Eckel J, Dietze-Schroeder D. Pathways leading to muscle insulin resistance--the muscle—fat connection. *Arch Physiol Biochem* 2006;112:105-113.

189. Taube A, Eckardt K, Eckel J. Role of lipid-derived mediators in skeletal muscle insulin resistance. *Am J Physiol Endocrinol Metab* 2009;297:E1004-E1012.

190. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet* 1963;1:785-789.

191. Yudkin JS, Eringa E, Stehouwer CDA. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. *Lancet* 2005;365:1817-1820.

192. Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. *Hypertension* 2009;54:1384-1392.

193. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. *Circulation* 2009;119:1661-1670.

194. Pinnick KE, Collins SC, Londos C, Gauguier D, Clark A, Fielding BA. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. *Obesity (Silver Spring)* 2008;16:522-530.

195. Rossi AP, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M, Di Francesco V, Barillari M, Pozzi Mucelli R, Zamboni M. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. *Obesity (Silver Spring)* 2011;in press.

196. van der Zijl NJ, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ, Blaak EE, Diamant M. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism. *J Clin Endocrinol Metab* 2011;96:459-467.

197. Vettor R, Milan G, Franzin C, Sanna M, De Coppi P, Rizzuto R, Federspil G. The origin of intermuscular adipose tissue and its pathophysiological implications. *Am J Physiol Regul Integr Comp Physiol* 2009;297:E987-E998.

198. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. *Lancet* 2010;375:2267-2277.

199. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. *Endocrinology* 2006;147:2458-2467.

200. Aron A, Zedalis D, Gregg JM, Gwazdauskas FC, Herbert WG. Potential clinical use of cardiopulmonary exercise testing in obstructive sleep apnea hypopnea syndrome. *Int J Cardiol* 2009;132:176-186.

201. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 2010;51:679-689.

202. Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, Scott DK, O'Doherty RM. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. *Diabetes* 2010;59:347-357.

203. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. *Gastroenterology* 2002;122:1649-1657.

204. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. *Obes Rev* 2004;5:27-42.

205. Day CP, James OF. Steatohepatitis: a tale of two "hits"? . *Gastroenterology* 1998;114:842-845.

206. Diehl AM. Lessons from animal models of NASH. *Hepatol Res* 2005;33:138-144.

207. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. *J Am Med Assoc* 2003;289:3000-3004.

208. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40:1387-1395.

209. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population-- examinations of 503 consecutive fatal traffic casualties. *Scand J Gastroenterol* 1977;12:593-597.

210. Clark J. The epidemiology of nonalcoholic fatty liver disease in adults. *J Clin Gastroenterol* 2006;40:S5-S10.

211. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. *J Clin Gastroenterol* 2006;40:S17-S29.

212. Hesham A, Kader H. Nonalcoholic fatty liver disease in children living in the obesogenic society. *World J Pediatr* 2009:245-254.

213. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J Clin Invest* 2008;118:829-838.

214. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. *Proc Natl Acad Sci U S A* 2009;106:15430-15435.

215. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O'Donnell CJ, Fox CS. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. *Hepatology* 2010;51:1979-1987.

216. Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. *Proc Natl Acad Sci USA* 2003;100:3077-3082.

217. Donnelly KL, Smith CI, Schwarzenberger SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest* 2005;115:1343-1351.

218. Gonzales-Yanes C, Sanchez-Margalet V. Signalling mechanisms regulating lipolysis. *Cell Signal* 2006;18:401-408.

219. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. *Gastroenterology* 2008;134:568-576.

220. Lavie L. Oxidative stress--a unifying paradigm in obstructive sleep apnea and comorbidities. *Prog Cardiovasc Dis* 2009;51:303-312.

221. Barceló A, Piérola J, de la Peña M, Esquinas C, Fuster A, Sanchez M, Carrera M, Alonso-Fernandez A, Ladaria A, Bosch M, Barbé F. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnea. *Eur Respir J* 2010;in press.

222. Jun JC, Drager LF, Najjar SS, Gottlieb SS, Brown CD, Smith PL, Schwartz AR, Polotsky VY. Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure. *Sleep* 2011;in press.

223. Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? *World J Gastroenterol* 2010;16:4243-4252.

224. Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk GY. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. *Dig Dis Sci* 2005;50:2338-2343.

225. Mathurin P, Durand F, Ganne N, Mollo JL, Lebrec D, Degott C, Erlinger S, Benhamou JP, Bernuau J. Ischemic hepatitis due to obstructive sleep apnea. *Gastroenterology* 1995;109:1682-1684.

226. Saibara T, Nozaki Y, Nemoto Y, Ono M, Onishi S. Low socioeconomic status and coronary artery disease. *Lancet* 2002;359:980.

227. Trakada G, Gogos C, Tsiamita M, Siagris D, Goumas P, Spiropoulos K. A case of ischemic hepatitis. *Sleep Breath* 2004;8:155-159.

228. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. *AJR Am J Roentgenol* 2007;189:W320-W323.

229. de Moura Almeida A, Cotrim HP, Barbosa DB, de Athayde LG, Santos AS, Bitencourt AG, de Freitas LA, Rios A, E. A. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. *World J Gastroenterol* 2008;14:1415-1418.

230. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. *World J Gastroenterol* 2008;14:3476-3483.

231. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. *Hepatology* 2009;49:306-317.

232. Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, Schweizter MA, Clark JM, Torbenson MS, Schwartz AR. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. *Am J Respir Crit Care Med* 2009;179:228-234.

233. Kallwitz ER, Herdegen J, Madura J, Jakate S, Cotler SJ. Liver enzymes and histology in obese patients with obstructive sleep apnea. *J Clin Gastroenterol* 2007;41:918-921.

234. Mishra P, Nugent C, Afendy A, Bai C, Bhatia P, Afendy M, Fang Y, Elariny H, Goodman Z, Younossi ZM. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. *Liver Int* 2008;28:1080-1086
.

235. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. *Hepatology* 2008;47:1916-1923.

236. Jouët P, Sabaté JM, Maillard D, Msika S, Mechler C, Ledoux S, Harnois F, Coffin B. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study. *Obes Surg* 2007;17:478-485.

237. Daltro C, Cotrim HP, Alves E, de Freitas LA, Boente L, Leal R, Portugal T. Nonalcoholic fatty liver disease associated with sleep apnea: just a coincidence? *Obes Surg* 2010.

238. Tanné F, Gagnadoux F, Chazouillères O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. *Hepatology* 2005;41:1290-1296.

239. Tatsumi K, Saibara T. Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis. *Hepatol Res* 2005;33:100-104.

240. Norman D, Bardwell WA, Arosemena F, Nelesen R, Mills PJ, Loredo JS, Lavine JE, Dimsdale JE. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. *Sleep 2008*;31:121-126.

241. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. *Chest* 2008;133:92-99.

242. Verhulst SL, Jacobs S, Aerts L, Schrauwen N, Haentjens D, Rooman RP, Gaal LV, De Backer WA, Desager KN. Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents? *Sleep Breath* 2009;13:207-210.

243. Savransky V, Bevans S, Nanayakkara A, Li J, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. *Am J Physiol Gastrointest Liver Physiol* 2007;293:G871-877.

244. Takayama F, Egashira T, Kawasaki H, Mankura M, Nakamoto K, Okada S, Mori A. A novel animal model on nonalcoholic steatohepatitis (NASH): hypoxemia enhances the development of NASH. *J Clin Biochem Nutr* 2009;45:335-340.

245. Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia predisposes to liver injury. *Hepatology* 2007;45:1007-1013.

246. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. *Am J Med* 2003;115:24S-28S.

247. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. *J Cardiometab Syndr* 2009;4:113-119.

248. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. *Eur J Cardiovasc Prev Rehabil* 2009;16:404-423.

249. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report *Circulation* 2002;106:3143-3421.

250. Adiels M, Olofsson S-O, Taskinen M-R, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008;28:1225-1236.

251. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia *Gastroenterology* 2007;132:2181-2190.

252. Olofsson S-O, Borèn J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. *J Intern Med* 2005;258:395-410.

253. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. *Nature Rev Endocrinol* 2010;6:335-346.

254. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. *Lipids* 2010;45:907-914.

255. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. *J Atheroscler Thromb* 2009;16:145-154.

256. Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Pickering TG, Quan SF. Relation of sleep disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. *Am J Epidemiol* 2001;154:50-59.

257. Roche F, Sforza E, Pichot V, Maudoux D, Garcin A, Celle S, Picard-Kossovsky M, Gaspoz JM, Barthélémy JC, Group. PS. Obstructive sleep apnoea/hypopnea influences high-density lipoprotein cholesterol in the elderly. *Sleep Med* 2009;10:882-886.

258. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. *Am J Respir Crit Care Med* 2007;175:190-195.

259. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. *Chest* 2008;134:686-692.

260. Gozal D, Sans Capdevila O, Kheirandish-Gozal L. Metabolic alterations and systemic inflammation in obstructive sleep apnea among non-obese and obese pre-pubertal children. *Am J Resp Crit Care Med* 2008;177:1142-1149.

261. Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. *Chest* 2007;132:843-851.

262. Iesato K, Tatsumi K, Saibara T, Nakamura A, Terada J, Tada Y, Sakao S, Tanabe N, Takiguchi Y, Kuriyama T. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. *Circ J* 2007;71:1293-1298.

263. Czerniawska J, Bielen P, Plywaczewski R, Czystowska M, Korzybski D, Sliwinski P, Gorecka D. Metabolic abnormalities in obstructive sleep apnea patients. *Pneumonol Alergol Pol* 2008;76:340-347.

264. Lefebvre B, Pepin JL, Baguet JP, Tamisier R, Roustit M, Riedweg K, Bessard G, Levy P, Stanke-Labesque F. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? . *Eur Respir J* 2008;32:113-120.

265. Tsioufis C, Thomopoulos K, Dimitriadism K, Amfilochiou A, Tousoulis D, Alchanatis M, Stefanadis C, Kallikazaros I. The incremental effect of obstructive sleep apnoea syndrome on arterial stiffness in newly diagnosed essential hypertensive subjects. *J Hypertens* 2007;25:141-146.

266. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit Care Med* 2005;172:613-618.

267. Tan KC, Chow WS, Lam JC, Lam B, Wong WK, Tam S, Ip MS. HDL dysfunction in obstructive sleep apnea. *Atherosclerosis* 2006;184:377-382.

268. Tokuda F, Sando Y, Matsui H, Koike H, Yokoyama T. Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. *Intern Med* 2008;47:1843-1849.

269. Li J, Grigoryev DN, Ye SQ, Thorne L, Schwartz AR, Smith PL, O'Donnell CP, Polotsky VY. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. *J Appl Physiol* 2005;99:1643-1648.

270. Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O'Donnell CP, Polotsky VY. Intermittent hypoxia induces hyperlipidemia in lean mice. *Circ Res* 2005;97:698-706.

271. Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. *J Appl Physiol* 2007;102:557-563.

272. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. Chronic intermittent hypoxia induces atherosclerosis. *Am J Respir Crit Care Med* 2007;175:1290-1297.

273. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* 2002;109:1125-1131.

274. Li J, Nanayakkara A, Jun J, Savransky V, Polotsky VY. Effect of deficiency in SREBP cleavage activating protein on lipid metabolism during intermittent hypoxia. *Physiol Genomics* 2007;31:273- 280.

275. Savransky V, Jun J, Li J, Nanayakkara A, Fonti S, Moser AB, Steele KE, Schweitzer MA, Patil SP, Bhanot S, Schwartz AR, Polotsky VY. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. *Circ Res* 2008;103:1173-1180.

276. Li J, Bosch-Marce M, Nanayakkara A, Savransky V, Fried SK, Semenza GL, Polotsky VY. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. *Physiol Genomics* 2006;25:450-457.

277. de Glisezinski Ie, Crampes F, Harant Ie, Havlik P, Gardette B, Jammes Y, Souberbielle JC, Richalet JP, Rivière D. Decrease of subcutaneous adipose tissue lipolysis after exposure to hypoxia during a simulated ascent of Mt Everest. *Pflügers Archiv European Journal of Physiology* 1999;439:134-140.

278. Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q, Haase VH. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. *Mol Cell Biol* 2009;29:4527-4538.

279. Drager LF, Li J, Shin MK, Reinke C, Aggarwal NR, Jun JC, Bevans-Fonti S, Sztalryd C, O'Byrne SM, Kroupa O, Olivecrona G, Blaner WS, Polotsky VY. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. *Eur Heart J* 2011;in press.

280. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. *Circulation* 2002;106:2137-2142.

281. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. *Am J Physiol Endocrinol Metab* 2009;297:E271-288.

282. Hall MH, Muldoon MF, Jennings JR, Buysse DJ, Flory JD, Manuck SB. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. *Sleep* 2008;31:635-643.

283. Jennings JR, Muldoon MF, Hall MH, Buysse DJ, Manuck SB. Self-reported sleep quality is associated with the metabolic syndrome. *Sleep 2007*;30:219-223.

284. Kaneita Y, Uchiyama M, Yoshiike N, Ohida T. Associations of usual sleep duration with serum lipid and lipoprotein levels. *Sleep* 2008;31:645-652.

285. Dochi M, Suwazono Y, Sakata K, Okubo Y, Oishi M, Tanaka K, Kobayashi E, Nogawa K. Shift work is a risk factor for increased total cholesterol level: a 14-year prospective cohort study in 6886 male workers. *Occup Environ Med* 2009;66:592-597.

286. Sookoian S, Gemma C, Fernández Gianotti T, Burgueño A, Alvarez A, Gonzáles CD, Pirola CJ. Effects of rotating shift work on biomarkers of metabolic syndrome and inflammation. *J Intern Med* 2007;261:285-292.

287. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, Rundle AG, Zammit GK, Malaspina D. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. *Sleep* 2007;30:1667-1673.

288. Beihl DA, Liese AD, Haffner SM. Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. *Ann Epidemiol* 2009;19:351-357.

289. Chen JC, Brunner RL, Ren H, Wassertheil-Smoller S, Larson JC, Levine DW, Allison M, Naughton MJ, Stefanick ML. Sleep duration and risk of ischemic stroke in postmenopausal women. *Stroke* 2008;39:3185-3192.

290. Brown DL, Feskanich D, Sánchez BN, Rexrode KM, Schernhammer ES, Lisabeth LD. Rotating night shift work and the risk of ischemic stroke. *Am J Epidemiol* 2009;169:1370-1377.

291. Fujino Y, Iso H, Tamakoshi A, Inaba Y, Koizumi A, Kubo T, Yoshimura T, Group. JCCS. A prospective cohort study of shift work and risk of ischemic heart disease in Japanese male workers. *Am J Epidemiol* 2006;164:128-135.

292. Puttonen S, Kivimäki M, Elovainio M, Pulkki-Råback L, Hintsanen M, Vahtera J, Telama R, Juonala M, Viikari JS, Raitakari OT, Keltikangas-Järvinen L. Shift work in young adults and carotid artery intima-media thickness: The Cardiovascular Risk in Young Finns study. *Atherosclerosis* 2009;205:608-613.

293. Lauderdale DS, Knutson KL, Rathouz PJ, Yan LL, Hulley SB, Liu K. Cross-sectional and longitudinal associations between objectively measured sleep duration and body mass index: The CARDIA Sleep Study. *Am J Epidemiol* 2009;170:805-813.

294. Patel SR, Blackwell T, Redline S, Ancoli-Israel S, Cauley JA, Hillier TA, Lewis CE, Orwoll ES, Stefanick ML, Taylor BC, Yaffe K, Stone KL, Group. OFiMRGSoOFR. The association between sleep duration and obesity in older adults. *Int J Obes* 2008;32:1825-1834.

295. Touchette E, Petit D, Tremblay RE, Boivin M, Falissard B, Genolini C, Montplaisir JY. Associations between sleep duration patterns and overweight/obesity at age 6. *Sleep* 2008;31:1507-1514.

296. Stranges S, Cappuccio FP, Kandala NB, Miller MA, Taggart FM, Kumari M, Ferrie JE, Shipley MJ, Brunner EJ, Marmot MG. Cross-sectional versus prospective associations of sleep duration with changes in relative weight and body fat distribution: the Whitehall II Study. *Am J Epidemiol* 2008;167:321-329.

297. Everson C, Szabo A. Recurrent restriction of sleep and inadequate recuperation induced both adaptive changes and pathological outcomes. *Am J Physiol Regul Integr Comp Physiol* 2009;297:R1430-R1440.

298. Nedeltcheva AV, Kessler L, Imperial J, Penev PD. Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. *J Clin Endocrinol Metab* 2009;94:3242-3250.

299. Nedeltcheva AV, Kilkus JM, Imperial J, Kasza K, Schoeller DA, Penev PD. Sleep curtailment is accompanied by increased intake of calories from snacks. *Am J Clin Nutr* 2009;89:126-133.

300. Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. *Nat Rev Endocrinol* 2009;5:253-261.

301. Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. *Proc Natl Acad Sci USA* 2008;105:1044-1049.

302. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, Chrousos GP. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. *J Clin Endocrinol Metab* 2004;89:2119-2126.

303. Bray MS, Young ME. Circadian rhythms in the development of obesity: potential role for the circadian clock within the adipocyte. *Obes Rev* 2007;8:169-181.

304. Young ME, Bray MS. Potential role for peripheral circadian clock dyssynchrony in the pathogenesis of cardiovascular dysfunction. *Sleep Med Rev* 2007;8:656-667.

305. Prasai MJ, Goerge JT, Scott EM. Molecular clocks, type 2 diabetes and cardiovascular disease. *Diabetes Vasc Dis Res* 2008;5:89–95.

306. Duez H, Staels B. Rev-erbα: an integrator of circadian rhythms and metabolism. *J Appl Physiol* 2009;107:1972-1980.

307. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. *Proc Natl Acad Sci USA* 2009;106:4453-4458.

308. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. *Chest* 2010;137:95-101.

309. Perrini S, Leonardini A, Laviola L, Giorgino F. Biological specificity of visceral adipose tissue and therapeutic interventions. *Arch Physiol Biochem* 2008;114:277-286.

310. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Group. DPPR. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.
.

311. Lindström J, Ilanne-Parikka P, Peltonen M, et al, Group. obotFDPS. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: the follow-up results of the Finnish Diabetes Prevention Study. *Lancet* 2006;368:1673–1679.

312. Pannain S, Mokhlesi B. Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism. *Best Pract Res Clin Endocrinol Metab* 2010;24:745-761.

313. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Porics W, Fahrbach K, Schoelles K. Bariatric surgery. A systematic review and meta-analysis. *J Am Med Assoc* 2004;292:1724-1737.

314. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. *Surgery* 2007;142:621-635.

315. Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. *Surg Obes Relat Dis* 2008;4:S47-S55.

316. Sjöström L, Narbro K, Sjöström D, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos A-K, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LMS, Study. otSOS. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 2007;357:741-752.

317. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocr Rev* 2006;27:73-100.

318. Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, Crocè LS, Masutti F, Tiribelli C. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. *BMC Gastroenterol* 2009;9:75.

319. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 2006;368:1696–1705.

320. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care* 2007;30:1487–1493.

321. Nauck MA, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, Group. ftL-S. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. *Diabetes Care* 2009;32:84-90.

322. Alhusaini S, McGee K, Schisano B, Harte A, McTernan P, Kumar S, Tripathi G. Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: Salicylate alleviates this stress. *Biochem Biophys Res Commun* 2010;397:472-478.

323. Fernández-Real JM, López-Bermejo A, Ropero AB, Piquer S, Nadal A, Bassols J, Casamitjana R, Gomis R, Arnaiz E, Pérez I, Ricart W. Salicylates increase insulin secretion in healthy obese subjects. *J Clin Endocrinol Metab* 2008;93:2523-2530.

324. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. *Diabetes Care* 2008;31:289-294.

325. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, Forbes J, de Courten B, Krakoff J. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. *Diabetologia* 2009;52:385-393.

326. Li M, Cheung BMY. Pharmacotherapy for obesity. *Br J Clin Pharmacol* 2009;68:804-810.

327. Redenius R, Murphy C, O'Neill E, Al-Hamwi M, Zallek SN. Does CPAP lead to change in BMI? . *J Clin Sleep Med* 2008;4:205-209.

328. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. *Am J Respir Crit Care Med* 2005;172:1590-1595.

329. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese males with OSA. *Eur Respir J* 2007;29:720-727.

330. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Collins B, Basta M, Pejovic S, Chrousos GP. Selective effects of CPAP on sleep-apnoea associated manifestations. *Eur J Clin Invest* 2008;38:585-595.

331. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. *Thorax* 2007;62:969-974.

332. Steiropoulos P, Papanas N, Nena E, Maltezos E, Bouros D. Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? *Curr Diabetes Rev* 2010;6:155-166.

333. Drager LF, Jun JC, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. *Curr Opin Endocrinol Diabetes Obes* 2010;17:161-165.

334. Cuhadaroglu C, Utkusavas A, Ozturk L, Salman S, Ece T. Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. *Lung* 2009;187:75-81.

335. Barcelo A, Barbe F, Llompart E, de la Pena M, Duran-Cantolla J, Ladaria A, Bosch M, Guerra L, Agusti AG. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. *Am J Respir Crit Care Med* 2005;171:183-187.

336. Sanner BM, Kollhosser P, Buechner N, Zidek W, Tepel M. Influence of treatment on leptin levels in patients with obstructive sleep apnoea. *Eur Respir J* 2004;23:601-604.

337. Trenell MI, Ward JA, Yee BJ, Phillips CL, Kemp GJ, Grunstein RR, Thompson CH. Influence of constant positive airway pressure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. *Diabetes Obes Metab* 2007;9:679-687.

338. Chin K, Nakamura T, Takahashi K, Sumi K, Ogawa Y, Masuzaki H, Muro S, Hattori N, Matsumoto H, Niimi A, Chiba T, Nakao K, Mishima M, Ohi M, Nakamura T. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. *Am J Med* 2003;114:370-376.

339. Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. *Respiration* 2009;78:141-146.

340. Chin K, Nakamura T, Shimizu K, Mishima M, Nakamura T, Miyasaka M, Ohi M. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. *Am J Med* 2000;109:562-567.

341. Chin K, Shimizu K, Nakamura T, Narai N, Masuzaki H, Ogawa Y, Mishima M, Nakamura T, Nakao K, Ohi M. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. *Circulation* 1999;100:706-712.

342. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. *Thorax* 2004;59:777-782.

343. Shneerson J, Wright J. Lifestyle modification for obstructive sleep apnoea. *Cochrane Database of Systematic Reviews* 2001 CD002875.

344. Tuomilehto HP, Seppä JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JO, Vanninen EJ, Kokkarinen J, Sahlman JK, Martikainen T, Soini EJ, Randell J, Tukiainen H, Uusitupa M, Group. KSA. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. *Am J Respir Crit Care Med* 2009;179:320-327.

345. Foster GD, Borradaile KE, Sanders MH, Millman RP, Zammit GK, Newman AB, Wadden TA, Kelley D, Wing RR, Pi-Sunyer FX, Reboussin D, Kuna ST, Study ftSA. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes. *Arch Intern Med* 2009;169:1619-1626.

346. Johansson K, Neovius M, Lagerros YT, Harlid R, Rössner S, Granath F, Hemmingsson E. Effect of a very low energy diet on moderate to severe obstructive sleep apnoea in obese men: a randomised controlled trial. *Br Med J* 2009;339:b4609.

347. Johansson K, Hemmingsson E, Harlid R, Trolle Lagerros Y, Granath F, Rossner S, Neovius M. Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up study. *BMJ* 2011;342:d3017.

348. Nerfeldt P, Nilsson BY, Mayor L, Udden J, Friberg D. A two-year weight reduction program in obese sleep apnea patients. *J Clin Sleep Med* 2010;6:479-486.

349. Grunstein RR, Stenlöf K, Hedner JA, Peltonen M, Karason K, Sjöström L. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. *Sleep 2007*;30:703-710.

350. Dixon JB, Schachter LM, O'Brien PE. Polysomnography before and after weight loss in obese patients with severe sleep apnea. *Int J Obes* 2005;29:1048-1054.

351. Haines KL, Nelson LG, Gonzales R, Torrella T, Martin T, Kandil A, Dragotti R, Anderson WM, Gallagher SF, Murr MM. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. *Surgery* 2007;141:354-358.

352. Rao A, Tey BH, Ramalingam G. Obstructive sleep apnoea (OSA) patterns in bariatric surgical practice and response of OSA to weight loss after laparoscopic adjustable gastric banding (LABG). *Ann Acad Med Singapore* 2009;38:587-593.

353. Martinez D, Basile BR. Sibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled study. *Sleep Med Clin* 2005;6:467-470.

354. Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. *Int J Obes* 2007;31:161-168.

355. Phillips CL, Yee BJ, Trenell MI, Magnussen JS, Wang D, Banerjee D, Berend N, Grunstein RR. Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. *J Clin Sleep Med* 2009;5:416-421.

356. Ferland A, Poirier P, Sériès F. Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. *Eur Respir J* 2009;34:694-701.

357. Williams G. Withdrawal of sibutramine in Europe. *Br Med J* 2010;340:c824.

358. Weaver TE, Grunstein RR. Adherence to Continuous Positive Airway Pressure Therapy: the challenge to effective treatment. *Proc Am Thorac Soc* 2008;5:173-178.

359. Han JC, Lawlor DA, Kimm SYS. Childhood obesity. *Lancet* 2010;375:1737-1748.

360. Mohamadi A, Cooke DW. Type 2 diabetes mellitus in children and adolescents. *Adolesc Med State Art Rev* 2010;21:103-119.

361. Berenson GS, Srinivasan SR, Bao W, Newman WPr, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med* 1998;338:1650-1656.

362. Spicuzza L, Leonardi S, La Rosa M. Pediatric sleep apnea: early onset of the 'syndrome'? *Sleep Med Rev* 2009;13:111-122.

363. Gozal D. Sleep, sleep disorders and inflammation in children. *Sleep Med* 2009;10:S12-S16.

364. Dayyat E, Kheirandish-Gozal L, Sans Capdevila O, Maarafeya MMA, Gozal D. Obstructive sleep apnea in children: relative contributions of body mass index and adenotonsillar hypertrophy. *Chest* 2009;136:137-144.

365. Wang JH, Chung Y-S, Cho Y-W, Yi JS, Bae JS, Shim MJ. Palatine tonsil size in obese, overweight, and normal-weight children with sleep-disordered breathing. *Otolaryngol Head Neck Surg* 2010;142:516-519.

366. Tauman R, Gulliver TE, Krishna J, Montgomery-Downs HE, O'Brien LM, Ivanenko A, Gozal D. Persistence of obstructive sleep apnea syndrome in children after adenotonsillectomy. *J Pediatr* 2006;149:803-808.

367. Kohler MJ, Thormaehlen S, Kennedy JD, Pamula Y, van den Heuvel CJ, Lushington K, Martin JA. Differences in the association between obesity and obstructive sleep apnea among children and adolescents. *J Clin Sleep Med* 2009;5:506-511.

368. Arens R, Sin S, Nandalike K, Rieder J, Khan UI, Freeman K, Wylie-Rosett J, Lipton ML, Wootton DM, McDonough JM, Shifteh K. Upper airway structure and body fat composition in obese children with obstructive sleep apnea syndrome. *Am J Respir Crit Care Med* 2011;183:782-787.

369. Eliot SK, Carolyn MDA. Pediatric obstructive sleep apnea syndrome. *Clinics in Chest Medicine* 2010;31:221-234.

370. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S, Diabetes. aobotIDFTFoEaPo. The Metabolic Syndrome in children and adolescents. *Lancet* 2007;369:2059-2061.

371. Weiss R, Dziura J, Burgert TS, Tamboriane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. *N Engl J Med* 2004;350:2362-2374.

372. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. *Arch Pediatr Adolesc Med* 2003;157:821-827.

373. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the third National Health and Nutrition Examination Survey. *Circulation* 2004;110:2494-2497.

374. Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. *Atherosclerosis* 2009;204:538-543.

375. Cali AMG, Caprio S. Ectopic fat deposition and the metabolic syndrome in obese children and adolescents. *Horm Res* 2009;71:2-7.

376. Li AM, Chan MH, Chan DF, Lam HS, Wong EM, So HK, Chan IH, Lam CW, Nelson EA. Insulin and obstructive sleep apnea in obese Chinese children. *Pediatr Pulmonol* 2006;41:1175-1181.

377. Verhulst SL, Schrauwen N, Haentjens D, Rooman RP, Van Gaal L, De Backer WA, Desager KN. Sleep disordered breathing and the metabolic syndrome in overweight and obese children and adolescents. *J Pediatr* 2007;150:608-612.

378. Hannon TS, Lee S, Chakravorty S, Lin Y-S, Arslanian SA. Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. *Int J Pediatr Obes* 2010.

379. Redline S, Storfer-Isser A, Rosen CL, Johnson NL, Kirchner L, Emancipator J, Kibler AM. Association between metabolic syndrome and sleep-disordered breathing in adolescents. *Am J Respir Crit Care Med* 2007;176:401-408.

380. Verhulst SL, Rooman RP, Van Gaal L, De Backer WA, Desager K. Is sleep-disordered breathing an additional risk factor for the metabolic syndrome in obese children and adolescents? *Int J Obes (Lond)* 2009;33:8-13.

381. Tsaoussoglou M, Bixler EO, Calhoun S, Chrousos GP, Sauder K, Vgontzas AN. Sleep-disordered breathing in obese children is associated with prevalent excessive daytime sleepiness, inflammation, and metabolic abnormalities. *J Clin Endocrinol Metab* 2010;95:143-150.

382. Dubern B, Aggoun Y, Boule M, Fauroux B, Bonnet D, Tounian P. Arterial alterations in severely obese children with obstructive sleep apnoea. *Int J Pediatr Obes* 2010;5:230-236.

383. Gozal D, Kheirandish-Gozal L. Obesity and excessive daytime sleepiness in prepubertal children with obstructive sleep apnea. *Pediatrics* 2009;123:13-18.

384. Alexopoulos EI, Gletsou E, Kostadima E, Kaditis D, Zakynthinos E, Gourgoulianis K, Kaditis A. Effects of obstructive sleep apnea severity on serum lipid levels in Greek children with snoring. *Sleep Breath* 2010;in press.

385. Tauman R, O'Brien LM, Ivanenko A, Gozal D. Obesity rather than severity of sleep-disordered breathing as the major determinant of insulin resistance and altered lipidemia in snoring children. *Pediatrics* 2005;116:66-73.

386. Kelly A, Dougherty S, Cucchiara A, Marcus CL, Brooks LJ. Catecholamines, adiponectin, and insulin resistance as measured by HOMA in children with obstructive sleep apnea. *Sleep* 2010;33:1185-1191.

387. Deboer MD, Mendoza JP, Liu L, Ford G, Yu PL, Gaston BM. Increased systemic inflammation overnight correlates with insulin resistance among children evaluated for obstructive sleep apnea. *Sleep Breath* 2011;in press.

388. Tauman R, Serpero LD, Sans Capdevila O, O'Brien LM, Goldbart AD, Kheirandish-Gozal L, Gozal D. Adipokines in children with sleep-disordered breathing. *Sleep* 2007;30:443-449.

389. Li AM, Ng C, Ng SK, Chan MMH, So HK, Chan I, Lam CWK, Ng PC, Wing YK. Adipokines in children with obstructive sleep apnea and the effects of treatment. *Chest* 2010;137:529-535.

390. Verhulst SL, Franckx H, Van Gaal L, De Backer WA, Desager K. The effect of weight loss on sleep-disordered breathing in obese teenagers. *Obesity (Silver Spring)* 2009;17:1178-1183.

391. Roemmich JN, Barkley JE, D'Andrea L, Nikova M, Rogol AD, Carskadon MA, Suratt PM. Increases in overweight after adenotonsillectomy in overweight children with obstructive sleep-disordered breathing are associated with decreases in motor activity and hyperactivity. *Pediatrics* 2006;117:e200-e208.

392. Apostolidou MT, Alexopoulos EI, Damani E, Liakos N, Chaidas K, Boultadakis E, Apostolidis T, Gourgoulianis K, Kaditis AG. Absence of blood pressure, metabolic, and inflammatory marker changes after adenotonsillectomy for sleep apnea in Greek children. *Pediatr Pulmonol* 2008;43:550-560.

393. Waters KA, Sitha S, O'Brien LM, Bibby S, de Torres C, Vella S, de la Eva R. Follow-up on metabolic markers in children treated for obstructive sleep apnea. *Am J Respir Crit Care Med* 2006;174:455-460.

394. Vijay LM, Naga C. Obstructive sleep apnea and nonalcoholic fatty liver disease: causal association or just a coincidence? *Gastroenterology* 2008;134:2178-2179.

395. Nakra N, Bhargava S, Dzuira J, Caprio S, Bazzy-Asaad A. Sleep-disordered breathing in children with metabolic syndrome: the role of leptin and sympathetic nervous system activity and the effect of continuous positive airway pressure. *Pediatrics* 2008;122:e634-e642.

Table 1. Organization of the review

1.INTRODUCTION

2. ADIPOSE TISSUE PATHOPHYSIOLOGY, INSULIN RESISTANCE AND METABOLIC SYNDROME

- 2.1 Types and distribution of the obesity
- 2.2 Mechanism of adipose tissue dysfunction
  - 2.2.1 Inflammation
  - 2.2.2 Hypoxia
  - 2.2.3 The lypoxygenase pathway and oxidative stress

3. OBESITY, INSULIN RESISTANCE, METABOLIC SYNDROME AND OSA

- 3.1 Clinical studies on metabolic syndrome abnormalities in OSA
- 3.2 Intermittent hypoxia mouse model

4. ECTOPIC FAT AND DYSLIPIDEMIA

- 4.1 Skeletal muscle adipose tissue in obesity and OSA
- 4.2 Hepatic steatosis and non alcoholic fatty liver disease in obesity an OSA
  - 4.2.1 Obesity
  - 4.2.2 OSA
  - 4.2.3 Intermittent hypoxia in animal models
- 4.3 Dyslipidemia in obesity and OSA
  - 4.3.1 Obesity
  - 4.3.2 OSA
  - 4.3.3 Intermittent hypoxia in animal models

5. THE METABOLIC EFFECT OF SLEEP LOSS

6. EFFECTS OF TREATMENT FOR OBESITY AND OSA

- 6.1 Therapeutic strategies in obesity and the metabolic impact of weight loss
- 6.2 Metabolic impact of CPAP treatment in OSA
- 6.3 Metabolic impact of weight loss in OSA

7. OBESITY AND OSA IN CHILDREN

- 7.1 Effect of treatment of pediatric OSA

8. FUTURE RESEARCH DIRECTION

Table 2. Studies on liver dysfunction, obesity and OSA

Study	Patients	Methods	OSA	Results
Singh et al, 2005 [224]	190 NAFLD patients	AST/ALT,liver biopsy, modified Berlin Questionnaire	46% of the sample reported symptoms of OSA	No difference in liver damage between pts with and without OSA
Jouët et al, 2007 [236]	62 morbidly obese (54 F)	AST/ALT, liver biopsy	OSA in 84.7% of the sample	Male sex and OSA increased the risk for increased AST/ALT. NASH and fibrosis not different between OSA and non-OSA
Kallwitz et al, 2007 [233]	85 morbidly obese (61 F)	AST/ALT, liver biopsy	AHI≥15 in 51% of the sample	Increased ALT in OSA pts; OSA tended to be associated with progressive liver disease
Mishra et al, 2008 [234]	101 morbidly obese	AST/ALT, liver biopsy	OSA in 83.5% of NASH+ and 72.7% of NASH- (NS)	Higher liver enzymes and OSA severity in NASH+ compared to NASH- pts
Campos et al, 2008 [235]	200 morbidly obese (168 F)	Liver biopsy	OSA diagnosed in 13.5% of the sample	OSA increased the risk of NASH (OR 4.0, CI 1.3-12.2)
Polotsky et al, 2009 [232]	90 morbidly obese (75 F)	AST/ALT, liver biopsy	RDI>5 in 81.1% of the sample; RDI 15±29	NASH in pts with severe O_2 desaturation during sleep
Daltro et al, 2010[237]	40 morbidly obese pts (26 F)	AST/ALT, liver biopsy	AHI>5 in 80% of the sample; median AHI 11 (6-30)	No significant association between OSA and liver enzymes or NASH
Tanné et al, 2005 [238]	163 suspected OSA	AST/ALT, liver biopsy	Moderate-severe OSA in 79% of the sample	Liver enzymes associated with BMI and OSA (OR 5.9, CI 1.2-29.2). NASH more severe in pts with AHI>50, but insulin resistance was a stronger factor
Tatsumi et al, 2005 [239]	83 OSA, 41 controls	Serum type III procollagen (latent NASH), CT liver/spleen ratio	Mean AHI 32.5	Non-obese pts (mean BMI 25.6 kg/m^2). Correlation between serum type III procollagen (marker of fibrosis) and O_2 desaturation during sleep. Hepatic steatosis unaffected by OSA
Norman et al, 2008 [240]	109 OSA	AST/ALT	Mean AHI 53	AST/ALT correlated with nocturnal hypoxemia
Chin et al, 2003 [338]	40 obese OSA	AST/ALT	Mean AHI 57	Increase in AST/ALT from evening to morning in untreated pts, blunted by acute and prolonged CPAP treatment
Kohler et al, 2009	94 OSA	AST/ALT	Mean ODI 42.4	Randomized controlled trial. Decrease in AST

[339]				after both therapeutic and subtherapeutic CPAP
Kheirandish-Gozal et al, 2008 [241]	518 snoring children, 142 overweight/obese	AST/ALT	OSA in 66.2% of the sample	Increased liver enzymes (>40 U/L) in obese OSA children, associated with insulin resistance and hyperlipidemia. Improvement after treatment
Verhulst et al, 2009 [242]	75 children & adolescents	AST/ALT	OSA in 44% of the sample	Increased liver enzymes associated with RDI and hypoxemia during sleep

Abbreviations: F: females; NAFLD: non alcoholic fatty liver disease; NASH: non alcoholic statohepatitis; AST: aspartate aminotransferase; ALT: alanine aminotransferase; AHI: apnea hypopnea index; RDI: respiratory disturbance index, ODI: oxygen desaturation index; OR: odds ratio, CI: confidence interval; BMI: body mass index; CT: computerized tomography.

Figure Legends

Figure 1. Schematic picture summarizing the functional consequences of visceral obesity in adipocyte, skeletal muscle, liver and vessel wall. The effects of OSA or intermittent hypoxia on the same variables are also summarized. See text for further details.